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INTRODUCTION 
Diagnosis and management of rheumatic diseases depend predominantly on 
clinical signs and symptoms. Although most patients present with a 
clear clinical picture and diagnosis is readily made, sometimes a 
diagnosis is established by exclusion of others and in some cases a de-
finite diagnosis is only made after a long period of time. Two impor-
tant rheumatic diseases are rheumatoid arthritis (RA) and systemic lu-
pus erythematosus (SLE). The spectrum of clinical presentations is 
large; in contrast/ the number of specific laboratory determinations is 
rather small. For RA the only serological parameter is the rheumatoid 
factor (RF) determination. In SLE, more assays are available to support 
the diagnosis: the so-called assays for antibodies against nuclear an-
tigens (ANA). 
Since about thirty years, rheumatologists have tried and succeeded to 
develop criteria for RA and SLE. These criteria were developed mainly 
for scientific purposes. It was thought that comparison between diffe-
rent centres and of different studies would become more reliable when 
the patients that were studied, fulfilled certain criteria. These cri-
teria are widely used and are nowadays also used by clinicians to es-
tablish a diagnosis in individual patients. It is almost unnecessary to 
say that common sense and clinical experience prevail over "criteria" 
and the diagnosis RA and SLE can be made without any reference to the 
above mentioned criteria. 
Because serology of auto-antibodies in rheumatic diseases, with special 
emphasis to diagnosis and prognosis, is the subject of this thesis, the 
criteria for RA and SLE will be discussed in short. 
Rheumatoid arthritis 
The criteria designed for the American Rheumatism Association (ARA) are 
shown in table 1. Although developed for research purposes a diagnosis 
based on these criteria can be made with different degrees of certain-
ty, depending on the number of criteria met by an individual patient. 
Some criteria have to be present for at least a continuous period of 
six weeks, others have to be observed by a physician. The list of cri-
teria is accompanied by a number of exclusions (1). Another set of cri-
teria of a more strict nature are the so-called "New York Criteria" and 
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Table 1. American Rheumatism Association criteria for the diagnosis of 
rheumatoid arthritis. 
1. Morning stiffness 
2. Pain on motion in at least one joint 
3. Swelling of one joint (soft tissue or fluid) 
4. Swelling of at least one other joint (soft tissue or fluid) 
5. Symmetrical joint swelling 
6. Subcutaneous nodules 
7. Typical roentgenographic changes in joints 
8. Positive test for rheumatoid factor in serum 
9. Poor mucine clot formation of synovial fluid 
10. Synovial histopathology consistent with RA 
11. Characteristic histopathology of rheumatoid nodule 
1) Classic RA: 7 criteria needed; Definite RA: 5 criteria needed; Pro-
bable RA: 3 criteria needed. 
2) To meet criteria 1 to 5, symptoms or signs must be present for at 
least 6 weeks. 
3) Criteria 2 to 6 must be observed by a physician. 
Reproduced from: Ropes MW et al: Bull Rheum Dis 9:175-176, 1958. 
were proposed in 1966. Of both sets of criteria only one criterium re-
presents a serological marker. This clearly depicts the lack of speci-
fic laboratory measures for the diagnosis RA. The laboratory determina-
tion mentioned is the rheumatoid factor (RF). This is an antibody of 
either IgM, IgG or IgA class, reacting with the Fc part of IgG molecu-
les. The origin and the role in etiopathogenesis of RA are not resolv-
ed. An antibody, first described in 1964, but only rarely mentioned in 
a Rheumatological textbook (2) or literature review (3) is the antipe-
rinuclear factor. The antigenic specificity of this antibody is not 
known, but specificity and sensitivity have been established: it com-
bines a rather low sensitivity with a fair specificity (4). The merits 
of this antibody and its relations with RA will be discussed below. 
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Systemic lupus erythenatosus 
Criteria for systemic lupus erythematosus (SLE) were developed by an 
ARA committee in 1971 (5) and published in a revised edition in 1982 
(6) (table 2). In the first set of 14 criteria two were regarding sero-
logic parameters. 1) A positieve LE-cell phenomenon; 2) chronic false 
positive syphylis test. One of the criteria covered hematological va-
lues for the red blood cell count, leucocytes and thrombocytes. The re-
vised edition of these criteria (6) contained also determinations of 
antinuclear antibodies (ANA), anti-doublestrended DNA antibodies (anti-
ds-DNA) and anti-Sm antibodies. So different serologie assays were 
recognized to be a basis for the diagnosis SLE. The criteria for SLE 
Table 2. 1982 Revision of American Rheumatism Association criteria for 
the diagnosis of systemic lupus erythematosus. 
1. Malar rash 
2. Discoid rash 
3. Photosensitivity 
4. Oral ulcers 
5. Arthritis 
6. Serositis 
7. Renal disorder 
8. Neurologic disorder 
9. Hematologic disorder 
10. Immunologic disorder 
11. Antinuclear antibody 
Unusual reaction to sunlight 
Oral or nasopharyngeal ulcers 
Non-erosive arthritis involving 2 or more 
peripheral joints 
Pleuritis or pleural effusion; pericarditis 
or pericardial effusion 
Persistant proteinuria of more than 0.5 
grams per day or cellular casts 
Seizures or psychosis with the exclusion of 
other causes (drugs or metabolic derange-
ments) 
Hemolytic anemia or leucopenia or lymphope-
nia or thrombocytopenia 
Positive LE cell preparation or anti-native 
DNA or anti-Sm or persistent false positive 
test for syphylis 
Abnormal titre in the absence of drugs known 
to cause "drug-induced lupus" 
1 ) A person is said to have systemic lupus erythematosus if any 4 or 
more of the 11 criteria are present, serially or simultaneously. 
Reproduced from: Tan EM et al: Arthritis Rheum 25:1271-1277, 1982. 
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are primarily designed for classification in research rather than for 
individual diagnosis. Mild cases would not be classified as SLE if the 
criteria were applied strictly. 
So for both RA and SLE criteria were designed. In the diagnosis of RA 
serologic determinations of antibodies play only a minor role, while 
the diagnosis of SLE can be supported by different serologic assays. It 
has to be reminded that the relations are not 100%. Both disease groups 
show patients who are negative for the antibodies mentioned. 
Besides these antibody specificities, a wide spectrum of auto-antibo-
dies is known to exist in patients with rheumatic diseases (7,8), all 
with their own relations with specific syndromes. Table 3 resumes in a 
very generalizing way the major "antinuclear antibody specificities" 
and their associated clinical syndromes. This list is not complete and 
contains anti-cytoplasmic antibodies. Here again, almost none of the 
Table 3. Major "antinuclear" antibodies in generalized auto-immune dis-
eases. 
antibody specificity associated diagnosis 
Anti-doublestranded DNA 
Anti-Sm 
Anti histone 
Anti-nRNP 
Anti-centromere 
Anti-Scl-70 (Anti Sc1-86) 
Anti-SS-A (anti 
Anti-SS-B (ant 
Ro)^| 
i La)J 
Systemic lupus erythematosus 
Systemic lupus erythematosus 
Drug-induced lupus erythematosus 
Mixed connective tissue disease 
CREST syndrome 
Systemic sclerosis 
Sjögrens syndrome 
Rheumatoid arthritis 
^Systemic lupus erythematosus 
Anti-Jo 
Anti-Mi 
Anti-Ku 
Anti-PMI 
С
Polymyositis, dermatomyositis 
and systemic sclerosis 
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relations is a 1 to 1 relation. This field of research is rapidly ex-
panding and as will be seen below, since new specific and sensitive 
techniques come available more specificities will be recognized in the 
near future. 
The remainder of this introduction will be divided in two parts. One 
considering antinuclear antibodies, the second part covering the anti-
perinuclear factor. The starting point of the studies described in the 
following chapters will be discussed. 
Antinuclear antibodies 
The LE-cell observed by Hargraves in 1948 (9) was the first recogni-
tion, as would be clear later, of an antinuclear antibody. The LE-cell 
test is after almost 40 years still in use (and is still one of the ARA 
criteria for SLE) but the assay is now considered to be tedious, insen-
sitive, aspecific and only of qualitative nature when compared with as-
says developed since the beginning of the sixties. Most widely used to 
test sera for the presence of ANA is an indirect immunofluorescence 
test (IFT). Tissue sections or microscope slide fixed cells are used as 
source of nuclear antigen. After incubation with patient serum and 
washing with buffer, the bound ANA can be detected by means of a fluor-
escein isothiocyanate (FITC) conjugated antiserum directed against 
human immunoglobulin and visualized by inspection with an UV illuminat-
ed microscope. Nuclear fluorescence indicates the presence of ANA in 
the serum, sera can be titrated to an endpoint in the IFT and different 
fluorescence patterns can be observed. Certain patterns were thought to 
represent certain antibody specificities. On its turn again, pattern 
identification has many drawbacks and has now become of less value. 
Many sera contain more than one antibody specificity and patterns are 
highly dependent on the dilution used: pattern may change upon increa-
sing dilutions (personal experience). For identification of ANA, de-
tected by means of IFT, a major division exists between antibodies 
against dsDNA and the other antibody specificities. 
Anti-dsDNA antibodies are readily detected by using Chritidia luciliae, 
a hemoflagellate with a mitochondrion containing high concentration of 
pure native DNA (dsDNA). Radioimmunoassays, in which antibodies bound 
to a radiolabeled dsDNA preparation are precipitated by means of a high 
salt concentration or polyethelene glycol are excellent assays to quan-
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titate anti-dsDNA in sera of patients. 
Other specificities of ANA can be identified by means of immunodiffu-
sion techniques in agar or agarose gels. Antigen and test serum are ap-
plied in small holes punched in a semi-solid support medium. After dif-
fusion of antigen and antibodies a precipitation line is formed. The 
procedure can be speeded and upgraded with regard to its sensitivity 
when a direct current is applied to the agarose gel (= counterimmuno-
electrophoresis, CIE). The antibodies, positively charged, move toward 
the cathode. Antigens, acidic and thus negatively charged , move into 
the opposite direction. Identities can be obtained by running test sera 
next to reference sera and inspecting precipitation lines for lines of 
identity. A second method used is enzyme treatment of the antigen pre-
paration, to show whether the antigen is resistant to or sensitive for 
the enzyme involved. Other, less often used assays are agglutination 
assays and enzyme linked immunosorbent assays (ELISA) with more or less 
purified antigens coated on a solid-fase. 
Since the beginning of the eighties, a new technique has come available 
for antibody testing, the so-called immunoblot assay (IBT). This is a 
technique developed in biochemistry research (10,11) but with a wide 
spectrum of applications (12). The technique as used in ANA testing 
will be described in short. Nuclear material is freed of RNA and DNA by 
digestion with enzymes. Remaining proteins are treated with chemicals 
to disrupt disulfide bridges (2-beta-mercaptoethanol) and to charge all 
proteins as negative molecules (sodium dodecyl sulfate, SDS). These 
proteins can now be separated irrespective of their normal electric 
charge, according to their relative molecular ratios, by means of elec-
trophoresis in a Polyacrylamide gel (PAAGE). This kind of gel provides 
a mesh of defined size, free to choose, and of neutral charge. Once the 
proteins are separated, they can be transferred to a sheet of nitrocel-
lulose again by employing their negative charge (electroblotting). Ni-
trocellulose is a solid support with high protein binding capacity. 
Once the nuclear proteins are transferred, strips of this so-called 
blot can be incubated with sera containing ANA. Antibodies will bind to 
their respective antigens and are visualized by means of an enzyme- or 
radioisotope-labeled antiserum against human immunoglobulin. Each anti-
gen and its antibodies are then defined as a nuclear protein with a 
specified molecular weight. This technique has contributed a lot in 
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recent years in the unraveling and defining of nuclear antigens. On the 
other hand it has been applied to serodiagnosis of patients sera. In 
this way it is a very sophisticated assay. In one serum (one strip) , 
different specificities of ANA can be recognized simultaneously. In 
chapter 2 a newly developed apparatus is described that facilitates si­
multaneous testing of 21 samples on one blot, without cutting the ni­
trocellulose in strips. But when a new assay is introduced in serology, 
it has to be validated. When for example the IBT is more sensitive 
than an IFT on chromosome spreads in measuring anticentromere antibo­
dies (АСА), the relation between this antibody and a syndrome called 
CREST (acronym for Calcinosis, Raynaud's phenomenon, oEsophageal dys­
function, Sclerodactyly and Teleangiectasia) might shift from specific 
to unspecific and thus invalidating the new test. 
The chapters 3 and 4 describe studies performed to validate the IBT in 
comparison with the CIE and the classical IFT on rat liver sections. 
Antiperinuclear antibody 
The discovery of the antiperinuclear factor (APF) was a matter of a 
lucky coïncidence and a sharp eye and mind. While screening SLE sera 
and control groups for ANA on human buccal mucosa cells, bright fluor-
escent granules in the cytoplasm of these cells were observed. It turn-
ed out to be a specific characteristic of sera of RA patients (4). In 
contrast with antinuclear factors, this serum factor was said to react 
with perinuclear antigens and was therefore called antiperinuclear fac-
tor. As a Dutch discovery it has remained mainly an "Old World" antibo-
dy and was only once mentioned in a study performed outside Europe 
(13). The subsequently published papers on this antibody all confirmed 
the original findings. This matter is discussed extensively in chapter 
7 of this thesis. In contrast to the ANA assays, the APF assay is in 
its essence the same in all publications. This makes comparison of all 
studies more reliable. 
One important point of difference between the studies published is the 
relation of APF to disease severity. Disease severity or disease acti-
vity are two entirely different matters. Especially in a disease like 
RA with its exacerbations and remissions. One only has to remember a 70 
year old lady with a 40-year history of RA. Her disease is now comple-
tely inactive and does not require any slow acting antirheumatic drug. 
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and wrists were performed and she has gone through two periods of 
severe vasculitis. She has now an inactive disease but her history 
would undoubtedly be interpreted as a severe form of RA. In most stu-
dies published, disease severity or activity are measured indirectly or 
imprecise. It is for this reason and because we had the impression that 
APF was more frequent in patients with more severe forms of the disease 
that we performed a retrospective clinical study to quantitate the pos-
sible relation. This study is described in chapter 5. 
The antigen present in human buccal mucosa cells was until now only 
"characterized" as keratohyaline bodies, in fact no more than a des-
criptive term. Cytohistochemical studies have not lead to a conclusive 
characterization. Since many different antibodies against Epstem-Barr 
virus (EBV) antigens or EBV-induced antigens are known to be present in 
RA patients, it seemed worthwhile performing a survey of different pa-
tients groups to invest a wide spectrum of antibodies related to RA. 
This study is described in chapter 6. 
In chapter 7 a review is given on the field of the APF and its rela-
tions to rheumatoid arthritis and rheumatoid factor. In this chapter 
the literature about ANA and rheumatoid arthritis is discussed as well. 
Together with an update on recent developments in the field of ANA 
testing and an outlook in future APF research, a summary of the results 
of the studies described in this thesis will be given in chapter 8. 
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SUMMARY 
To facilitate the use of Western blots for the detection of antibo-
dies, we developed an incubation apparatus. The use of this apparatus 
simplifies the incubation of blots with antisera and thus allows the 
testing of large numbers of sera. It eliminates artefacts caused by 
the use of loose strips. The introduction of a pressure bag in the low-
er lid of the apparatus secures a steady pressure over the entire blot, 
a feature lacking in a presently available commercial apparatus. The 
detection of antinuclear antibodies is presented as an example for the 
use of this so-called blot, or Westgeest incubator. 
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INTRODUCTION 
The Western blotting technique is frequently used to study antigen-
antibody interactions, especially when the antigen is not available in 
a pure form (Towbin et al., 1979; Tsang et al., 1983). An example of 
this technique is offered by the analysis of antinuclear antibodies 
present in the serum of patients suffering from rheumatic diseases. 
Transfer of electrophoretically separated nuclear proteins to nitrocel-
lulose, followed by incubation of (strips of) blots thus obtained with 
sera of patients with generalized autoimmune diseases (White et al., 
1982) or with monoclonal antibodies (Lerner et al., 1981), makes it pos-
sible to differentiate between such antinuclear antibodies (ANA). This 
characterization allowed the identification of disease-specific, so-
called "marker" antibodies (Van Venrooy et al., 1985). However, the ma-
nipulation of many nitrocellulose strips during incubation and washing 
procedures and the tedious work of aligning the strips afterwards makes 
the immunoblotting technique rather impractible and time-consuming. To 
solve this, we developed an apparatus which makes it possible to incu-
bate large numbers of samples with one uncut blot. In this communica-
tion, we present technical details of this apparatus. An example of its 
use in detection and characterization of ANA antigens is also given. 
MATERIALS AND METHODS 
Sera. Sera containing antinuclear antibodies (ANA) were obtained from 
various groups of patients with defined disorders and from patients 
whose sera were sent to our Institute for routine determination of ANA. 
Disease groups included Systemic Lupus Erythematosus [SLE; patients 
fulfilling at least 4 of the revised criteria of the American Rheuma-
tism Association (Tan et al., 1982a)], Rheumatoid Arthritis [RA; pa-
tients fulfilling 7 or more of the ARA criteria (Rodnan et al., 1973)], 
Sjogren's Syndrome and Scleroderma (Masi and Rodnan, 1981). Normal con-
trol sera were obtained from healthy blood donors. All sera were stored 
at -20oC. Sera were tested for the presence of ANA by different methods. 
Indirect immunofluorescence (IFT) on rat-liver sections, HEp-2 cells or 
chromosome spreads of HEp-2 cells was performed according to the method 
as described by Tan et al. (1980). Precipitating antibodies against 
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extractable nuclear antigens were demonstrated with the counterimmuno-
electrophoresis (CIE) (Kurata and Tan, 1976). Reference sera, distri­
buted by the Arthritis Foundation (CDC), Atlanta were used to establish 
identity of the patients' sera (Tan et al., 1982b). 
Шасіеаг antigen. Nuclear antigen was prepared as described by Hinter­
berge r et al. (1983) with minor modifications (Westgeest et al., 1985). 
Briefly, 2xl09 HeLa cells were collected from cultures in logarithmic 
growth phase, washed in isotonic buffer (90 mM KCl, 10 mM NaCl, 50 mM 
phosphate buffer, pH 7.5), and lysed in a hypotonic, detergent-contain­
ing buffer (50 mM KCl, 10 mH NaCl, 50 mM phosphate buffer, pH 7.5, 1 mM 
EDTA and 0.5% (v/v) Nonidet P-40) by shearing through a 1.2 χ 40 mm 
needle. The lysate was centrifuged over a sucrose cushion (800 mM su­
crose, 25 mM KCl, 1 mM EDTA, 1% (v/v) Nonidet P-40) for 15 min at 2000 
g. The pellet was resuspended in 5 ml 110 mM NaCl, 1.5 mM MgCla, 10 mM 
Tris, pH 7.5, 250 mM sucrose and, subsequently, nuclei were disrupted 
by sonication. The sonicate (t 7.5 ml) was treated with DNase II and 
RNase A (Sigma) at a final concentration of 500 and 100 pg/ml, respec­
tively, for 1 h at room temperature. An equal volume of sample buffer 
(125 mM Tris HCl, pH 6.8, 5% 2-mercaptoethanol, 2% sodiumdodecyl sul­
fate (SDS), 10% glycerol, 0.01% bromophenolblue) was added to the nu­
clear antigen and the sample was heated to 100oC for 5 min. After cen-
trifugation, the supernate was aliquoted in 500 μΐ and stored at -20oC. 
All the buffers throughout the preparation contained 1 mM phenylmethyl-
sulfonylfluoride (PMSF). 
Electrophoresis and blotting. Gel electrophoresis was performed accor­
ding to Laemmli (1970), using 1.5 mm, 13% Polyacrylamide SDS gels. Nu­
clear preparation was layered on top of the stacking gel (5%) over the 
entire width (14 cm). Electrophoresis was performed at 50 mA per gel at 
10oC until the bromophenol blue reached the anodal end of the gel. Gels 
were blotted overnight to nitrocellulose (BA85, 0.45 pm Schleicher & 
Schuil) at 100 mA through a surface of 225 cm2 at 40C according to Tow-
bin et al. (1979). Blots were dried and stored at room temperature. 
Blot incubator. Technical details of the Westgeest incubator are shown 
in Figs. 1 and 2. The essential parts are two 20-mm-thick Plexiglass 
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plates (ICI), size 180x160 mm. In the inner side of the upper lid, 
twenty-one hollows of 4x120 mm, depth 6.5 mm, are milled, separated by 
a rim of 2 mm. The lower plate is milled over an area of 138x134 mm at 
1' 0»I134 H 
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Fig. 1 - Drawing of the blot incubator. The apparatus is constructed 
from 20-inm-thick Plexiglass. Panel 1, overview of all parts in consecu­
tive order. Upper plate (A) with holes (A') for application of sample 
and lower plate (F) are clenched by eight bolts and nuts (H and I). The 
lower plate contains the inflatable bag (E) with the valve (E') stick­
ing through the centre hole (G). Between the rubber bag and the upper 
plate are the nitrocellulose blot (C) and a 1-mm-thick silicone pad (D). 
The apparatus is mounted on a stand (I). Panel 2, cross section of up­
per (A) and lower lid (F) with central hole (G) for the valve from the 
air bag. The application holes and the incubation chambers are seen 
in the upper lid. 
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a depth of 8 mm with a hole in the centre. This lower lid contains an 
inflatable rubber bag, 138x134 mm size, with a valve sticking through 
the centre hole. The rubber bag is covered by a 1-mm-thick silicone 
rubber pad (Phoenix, Hamburg), precisely fitting in the 138xl34-mm hole. 
The two lids can be clenched together by eight bolts and nuts. When a 
nitrocellulose blot is mounted between the upper lid and the silicone 
rubber pad, the bolts and nuts tightened and the rubber bag inflated up 
to a pressure of 0.2 MPa, the hollows in the upper lid form twenty-one 
(4x120 mm size) incubation chambers. Samples are applied through holes 
in the upper lid. The incubator is mounted on a Plexiglas stand. Du-
ring incubations, the incubator is constantly agitated on a shaking 
platform. 
Fig. 2 - Photograph of the blot incubator, loaded with a nitrocellulose 
blot and mounted. The application holes and 21 incubation chambers are 
visible in the upper lid. 
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Detection of antibodies. All procedures were performed at room tempera-
ture. Prior to incubation, a blot was soaked for 30 min in a phosphate-
Tween buffer (10 mM phosphate buffer, pH 7.2, 140 mM NaCl, 0.1% Tween 
20; PBST). The blot was mounted in the incubator and incubated with 
sera diluted in PBST. After 2 h, each incubation chamber was exhausti-
vely rinsed with three changes of PBST. To detect bound antibodies, we 
routinely used a horse-radish peroxidase-conjugated rabbit-anti-human 
IgG antiserum (DAK0, cat. no. p214) diluted 1:500 in PBST, supplemented 
with 10% normal rabbit serum to reduce background staining. After 2 h 
of incubation, each incubation chamber was again washed with three 
changes of PBST. The pressure valve was opened and the incubator dis-
mantled. The intact blot was washed 2 times in a fresh volume of PBST, 
10 min for each change. The staining procedure was a modification from 
the procedure described by Hawkes et al. (1982). One ml of ethanol con-
taining 10 mg 4-chloro-l-naphtol (Sigma) was added to 99 ml PBS with 
3.5 mM H2O2. This volume was sufficient for one blot. The reaction 
was stopped by rinsing with tap water. Blots were airdried and stored 
in the dark. 
RESULTS AND DISCUSSION 
Problems involved in working with loose strips have led to the idea of 
working with intact blots. In the prototypes we developed some 4 years 
ago, two plates were very securely leveled. In one of the plates, the 
incubation hollows were milled. Clenching was achieved by bolts and 
nuts on the edge of the plates. Hoef er Scientific Instruments (San 
Francisco, CA, USA) recently introduced a similar apparatus on the mar-
ket, the Deca-Probe PR 200. This apparatus suffers from the same draw-
backs as our prototypes did: no equal pressure over the entire blot and, 
resulting from this, the limit of 10 lanes per blot. Another drawback 
of their apparatus is that rather large amounts of reagents are needed 
per lane. We found a solution to the pressure problem by the introduc-
tion of a pressure bag in the lower lid. This bag assures a steady 
pressure over the entire blot; it adds only little weight to the incu-
bator and it is easy to manipulate. The size of the rubber bag has to 
be a few millimeters over the size of the blots employed to ensure the 
isolation of the incubation chambers. 
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To evaluate leaking from one lane to the other, we mounted a nitrocel­
lulose sheet in the incubator and filled some lanes with human serum, 
diluted 1:10 in PBST. The neighbouring lanes were incubated with PBST 
only. Samples of these neighbouring lanes were tested for the presence 
of human IgG and IgM [by means of an ELISA, (Sauerwein et al., 1986)] 
and concentrations were calculated as a percentage of the initial con­
centration in the lane containing the serum. After 6 h of incubation, 
no IgG or IgM could be detected in the test lanes (lower limit of the 
ELISA used was 10 ng/rnl). After 24 h, the concentrations of IgG and 
ΙφΙ were 0.5 and 0.1%, respectively, relative to the neighbouring lane. 
It is our experience that this leakage or diffusion is not only depen­
dent on time but also on pore size of the nitrocellulose and on the 
molecular weight of the molecule monitored to quantitate leakage (data 
not shown). 
Fig. 3 shows a photograph of a nitrocellulose blot with nuclear antigen, 
incubated with patients' sera (diluted 1:50 in PBS containing 0.1% 
Tween-20) and peroxidase-conjugated antiserum against human IgG. The 
imprint of the upper lid with the 21 hollows is clearly visible. Lanes 
numbered 2, 3, 18, 19 and 20 contained normal human serum (NHS). Lane 4 
was incubated with serum from an SLE patient, antibodies against nu­
clear antigens Sm and nRNP in this serum had been identified by using 
CIE. No staining of Sm and/or nRNP is seen in lane 3, whereas the pre­
sence of these antibodies results in strongly stained nRNP- and Sm-
bands in lane 4 (nRNP: 68 kD,- Sm 26 and 16 kO). Lanes 11 and 12 con­
tained sera that were identified by IFT as anticentromere-positive sera. 
Both sera show the presence of a 19-kO band in the immunoblot. One of 
these sera (no. 11) was obtained from a patient with scleroderma, the 
other (no. 12) was from a patient with Sjogren's syndrome. Three anti-
SS-B-positive sera were incubated in lanes 8, 9 and 10; these antibo­
dies stain a 50-kD band. Lanes 13 and 14 show, among other unknown 
specificities, the presence of anti-SS-A antibodies (60 kD) in two dif­
ferent sera. Sera incubated in lanes 5, 6 and 7 show the presence of 
antibodies reactive with known antigens: Sm, nRNP (7) and Scl-86 (Van 
Venrooy et al., 1985). Lanes 1, 15 and 21, incubated with PBST and per­
oxidase-conjugated antiserum against human IgG, show some crossreacti-
vity of this second antibody with histones present in the nuclear pre-
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paration. Next to well-defined antigens, most sera also contain unknown 
antibody specificities, e.g. lanes 4 up to 15 and 18. The presence of 
these antibodies has been shown in normal as well as in patients' sera 
(Westgeest et al., 1985), but their importance has not yet been resol­
ved. Lanes 16, 17 and 18 show an important of advantage of the des-
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Fig. 3 - Nitrocellulose blot of a gel, loaded with nuclear antigen and 
incubated with sera as described in Materials and Methods. 
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cribed apparatus. As long as a blot remains intact, very small dif-
ferences in molecular weight of antigenic proteins are easily identi-
fied. Lanes 16 and 18 contained two different sera. Number 16 shows 
the presence of antibodies against SS-B antigen (50 kD). Lane no. 18 
was incubated with a serum of a healthy blood donor, which was found 
to contain antibodies against a slightly smaller antigen. That the 
antigenic determinants are not on the same protein is clearly shown in 
lane 17 where the two sera were mixed before incubation with the blot. 
In conclusion, we feel that the use of this apparatus greatly simpli-
fies the incubation of blots with antisera. Use of this apparatus is 
time- and reagent-saving, and facilitates testing of large numbers of 
samples in a very comfortable way. Above all, it eliminates artefacts, 
caused by misalignment of strips. 
32 
REFERENCES 
Hawkes, R., E. Niday, J. Gordon: 1982, Anal. Biochem. 119, 142. 
Hinterberger, M., I. Pettersson, J.A. Steitz, 1983, J. Biol. Chem. 258, 
2604. 
Kurata, N.. E.M. Tan, 1976, Arthr. Rheum. 19, 574. 
Laemmli, U.K., 1970, Nature 227, 680. 
Lerner, E.Α., M.R. Lerner, CA. Janeway, J.A. Steitz, 1981, Proc. Nati. 
Acad. Sci. USA 78, 2737. 
Masi, Α., G.P. Rodnan, 1981, Bull. Rheum. Dis. 31, 1. 
Rodnan, G.P., С McEwen, S.L. Wallace, 1973, JAMA (suppl.) 224, 799. 
Sauerwein, R.W., G.C. Mudde, W.G.J, van der Meer, W.C. Vooys, E. Rose-
muller, G.C. de Gast, L.A. Aarden, 1988, Clin. Immunol. Immunopathol. 
46, 1. 
Tan, E.M., G.P. Rodnan, I. Garcia, Y. Moroi, M.J. Fritzler, С Peebles, 
1980, Arthr. Rheum. 23, 617. 
Tan, E.M., M.J. Fritzler, J.S. McDougal, F.C. McDuffie, R.M. Nahamura, 
M. Reichlin, C.B. Reimer, G.C. Sharp, P.H. Schur, M.R. Wilson, R.J. 
Winchester, 1982a, Arthr. Rheum. 25, 1003. 
Tan, E.M., A.S. Cohen, J.F. Fries, A.T. Masi, D.J. McShane, N.F. Roth-
field, J. Green Schaller, N. Talal, R.J. Winchester, 1982b, Arthr. 
Rheum. 25, 1271. 
Towbin, H-, T. Staehelin, J. Gordon, 1979, Proc Natl. Acad. Sci. USA 
76, 4350. 
Tsang, V.C.W., J.M. Peralta, A.R. Simons, 1983, in: Methods in Enzymo-
logy, eds. J.J. Langone and H. Van Vunakis, Vol. 92, p. 377 (Acade­
mic Press, New York). 
Venrooy, W.J. van, S.O. Stapel, H. Houben, W.J. Habets, C.G.M. Kallen­
berg, E. Penner, L.B. van de Putte, 1985, J. Clin. Invest. 75, 1053. 
Westgeest, Α.Α.Α., H.G. van den Brink, Α.J.G. Swaak, R.J.T. Smeenk, 
1985, in: 33rd Colloquium, Protides of the Biological Fluids, éd. H. 
Peeters, p. 405 (Pergamon Press, Oxford). 
White, P.J., P.B. Billings, S.O. Hoch, 1982, J. Immunol. 128, 2751. 
33 

CHAPTER 3 
ANTINUCLEAR ANTIBODIES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: 
A COMPARISON OF COUNTERIMMUNO-ELECTROPHORESIS AND IMMÜNOBLOTTING 
AAA Westgeest, HG van den Brink, J de Jong, AJG Swaak and RJT Smeenk 
Published in Rheumatology International 
35 
SUMMARY 
Traditionally, the mostly used method to identify antinuclear antibody 
(ANA) specificities is the counter immuno-electrophoresis technique 
(CIE), in which a salt extract of rabbit thymus powder (so-called ex-
tractable nuclear antigen or ENA) serves as source of antigen. Recent-
ly, the immunoblotting technique (IBT) has been introduced in the sero-
logy of antinuclear antibodies. A nuclear extract of HeLa cells is 
generally used as antigen in this method. In this paper, we compared 
both methods using sera of patients with active systemic lupus erythe-
matosus (SLE). Only anti-Sm, anti-RNP and anti-SS-B were taken into 
consideration, as the former technique only allowed the identification 
of these specificities. Within these restrictions, we found that, out 
of 77 patients with SLE, 21 had CIE-detectable antibodies in their cir-
culation and 29 IBT-detectable antibodies. Anti-RNP and anti-SS-B were 
detected more frequently with the CIE than with the IBT; anti-Sm, on 
the other hand, was detected more frequently with the IBT than with the 
CIE. Several significant correlations were found between incidences of 
measured antibody specificities and disease features. The presence of 
anti-RNP (both if measured with the IBT or with the CIE) was found to 
be negatively correlated with nephritis. If measured with the IBT, the 
presence of anti-Sm was negatively correlated with hematological dis-
orders and the presence of anti-SS-B positively correlated with renal 
involvement. Only if measured with the CIE, the presence of anti-SS-B 
was negatively correlated with central nervous system disorders. 
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INTRODUCTION 
The presence of antinuclear antibodies (ANA) in sera of patients with 
generalized autoimmune diseases is well documented. The use of the in-
direct immunofluorescence technique (IFT) employing different substra-
tes (e.g. rat liver or kidney sections (1) or cell lines like HEp-2 
(2)) and the description of different staining patterns, suggested the 
existence of many different antibody specificities. In the past two 
decades, these specificities have been characterized and defined by 
means of different techniques (3). Biochemical extraction procedures 
and enzymatic treatment of antigen combined with immunodiffusion and 
agglutination techniques have given insight into the multispecificity 
of ANA: anti-double-stranded DNA (anti-dsDNA), anti-histone, anti-Sm, 
anti-RNP, anti-SSA, anti-SSB and many other specificities have been 
described. Relations between specific types of ANA and defined diseases 
or syndromes have also been claimed (3,4). 
Recent developments in serology have propagated the search for more 
sophisticated and quantitative assays for the different antibody speci-
ficities. When purified antigens are available, specific ANA measure-
ment may result in improved clinical relevance. For example, it has 
been shown that anti-dsDNA is of diagnostic and prognostic importance 
in systemic lupus erythematosus (SLE): this antibody was found to be 
specific to SLE and -under defined conditions- a steady increase of 
anti-dsDNA predicts an upcoming exacerbation (5). A different approach 
was taken with the introduction of the so-called immunoblotting tech-
nique (IBT) in ANA research (6). This technique allows identification 
of different ANA specificities without prior purification of the va-
rious antigens. The IBT makes it feasible to obtain improved correla-
tions between disease symptoms or syndromes and ANA patterns. The aim 
of this study was to compare the IBT with the CIE for the detection of 
autoantibodies against extractable nuclear antigens in sera of patients 
with SLE, i.e. to study whether the use of the IBT would lead to better 
correlations with disease symptoms than the CIE. We focussed our atten-
tion on three antibody specificities that can indeed be measured by 
both methods: anti-Sm, anti-RNP and anti-SSB, and used both methods as 
they have been published, i.e. in the IBT, a nuclear extract of HeLa 
cells served as antigen, in the CIE a salt-extract of rabbit thymus 
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powder. 
MATERIALS AND METHODS 
Sera and patients. Sera used in this study were obtained from 77 pa-
tients who fulfilled the revised ARA criteria for SLE (7). They were 
collected during a period of exacerbation of the disease, which was de-
fined by the occurrence of one or more major disease symptoms (8). 
Minor disease symptoms were mainly restricted to the musculoskeletal 
system and the skin and these could be controlled by an increase in 
prednisolone dosage (5-15 mg/day) without the need for admission to hos-
pital. Major features were characterized by at least one of the follow-
ing: renal impairment, serositis, anemia (Hb<7 g/dl [70 g/1]) and/or 
leukopenia (white cell count <4xl09/l) and/or thrombocytopenia (plate-
let count <50xl09/l), neurological or psychiatric symptoms. These 
features always led to hospitalization, and the dosage of prednisolone 
was increased to more than 20 mg/day. Episodes in which disease symp-
toms could be explained by causes other than SLE were excluded from the 
study. 
The disease of patients with pre-existing renal involvement was consi-
dered to be inactive when no significant alterations took place in 
creatinine values, proteinuria, and urine sediment. An increase in 
proteinuria or any other evidence of further deterioration of the renal 
function, in the absence of other causes (such as pyelonephritis not 
related to SLE), were recorded as exacerbations of renal disease. Renal 
function was assumed to have deteriorated when urinary protein increa-
sed to at least 1 g/2A h, or when there was an increase in red blood 
cell (RBC) casts in the urinary sediment, or a decrease in glomerular 
filtration rate (GFR) of more than 20%. An increase in urinary protein, 
sediment abnormalities, or a decrease in GFR were considered to be sig-
nificant only if these were observed on at least three consecutive days. 
Sera of healthy blood donors served as normal controls. All sera were 
stored at -20oC until use. 
Anti-dsDNA detection on Crithidia luciliae. Anti-dsDNA was measured as 
described by Aarden et al. (9). Briefly, twofold serial dilutions, 
starting at 1:10 of sera made with phosphate-buffered saline (PBS, 0.01 
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M phosphate, pH 7.4, 0.14 M NaCl), were incubated with the slides for 
30 min at room temperature (RT). Slides were washed for 30 min with 
PBS (3 changes). After 30 min of incubation with a FITC-conjugated 
anti-human immunoglobulin sheep antiserum (this institute, batch: 
CLB-SH17-1-F9), slides were again washed for 30 min with PBS, and fi-
nally mounted with a solution of 65% (w/v) sucrose in PBS (pH 8.0) with 
0.5 Mg/ml propidium-iodide. Kinetoplast fluorescence was taken as 
anti-dsDNA activity, whereas the propidium-iodide served as a counter-
stain to facilitate localization of kinetoplasts. 
Assay for precipitating antibodies against extractable nuclear antigens. 
Antibodies against extractable nuclear antigens (ENA) were detected as 
described by Kurata and Tan (10), using an extract of rabbit thymus 
powder (Pel Freez, Arkansas) as the source of antigen. Briefly, 1.5 g 
of rabbit thymus powder (Pel Freez) was mixed for 4 h with 25 ml of PBS 
at 40C. The mixture was centrifuged for 20 min at 20 000 rpm. The 
supernatant was recentrifuged once, aliquoted and frozen at -70oC. 
Such a preparation contained about 10 mg/ml of protein. Glass plates 
(8x12 cm) were covered with 1% agarose gels, made in electrophoresis 
buffer (0.05 M barbitene buffer, pH 8.2) containing 0.01% thimerosal. 
Holes, 4 mm in diameter, were punched 5 mm apart from each other and 
filled with antigen and serum. Electrophoresis was carried out -with 
the antigen holes on the cathode side- at 120 V, 20 mA per plate for 
about 45 min, or until a solution of 0.25 mg/ml of bromophenol blue in 
electrophoresis buffer had run for 1.7 cm. Precipitation lines were 
stained with a solution of 1% Coomassie Brilliant Blue in fixing solu-
tion (H2O: ethanol: acetic acid = 9:9:2). 
Plates were read and confirmation of an observed reactivity as either 
anti-RNP, anti-Sm or anti-SSB was achieved by: 1) comparison with re-
ference sera (Arthritis Foundation, CDC, Atlanta, (11)) where lines of 
complete identity were searched for, and 2) sensitivity of the precipi-
tation reaction to RNase treatment of the antigen. 
Immunoblotting for the detection of antinuclear antibodies. The tech-
nique employed was described earlier (12). Briefly, nuclear antigen was 
prepared from HeLa cells that were lysed in a hypotonic, detergent con-
taining buffer (0.05 M KCl, 0.01 M NaCl, 0.05 M phosphate buffer, pH 
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7.5, 1 mM EDTA and 0.5% (v/v) Nonidet P-АО). The nuclei were isolated, 
sonicated and digested with DNase and RNase. After electrophoresis in 
SDS Polyacrylamide gels (13) and transfer of the nuclear proteins to 
nitrocellulose (14), blots were incubated with patients' sera, in a 
specially developed blotting incubator that allowed simultaneous tes­
ting of 21 samples on one blot (15). Sera were diluted 1:100 in PBS 
containing 0.1% Tween (PBST) and incubated with the blot for 2 h at 
room temperature. After washing with PBST (3 changes of 15 min each), 
bound antibodies were detected by a horse-radish peroxidase-conjugated 
rabbit-anti-human IgG antiserum (Dakopatts, cat. nr. P215), diluted in 
PBST containing 10% normal rabbit serum. Staining of the blots was 
performed with 4-chloro-l-naphtol (Sigma, cat. nr. C8890) as substrate 
(16). Standard sera were applied on each blot as positive controls and 
as reference samples, to allow identification of anti-KNP (70-kD band), 
anti-Sm (28-29-kD doublet, BB', and a 13-kD band, D) and anti-SSB (54-
kO band). An illustration of an immunoblot obtained using various 
sera and the specially developed blotting incubator is given in fig­
ure 1. 
Statistics. To calculate whether an observed frequency of an autoanti­
body in a clinical subgroup of patients differed significantly from the 
expected frequency in a normal distribution, two-by-two tables of pa­
tients with/without the clinical symptoms versus the presence/absence 
of the studied autoantibody were made and analyzed for possible signi­
ficant correlations by chi-square calculation on a ZX Spectrum micro­
computer. 
RESULTS 
Relation between anti-dsDNA titer and the incidence of anti-RNP, anti-
Sm and anti-SSB. All sera were positive in the IFT on Crithidia 2uci-
liae for anti-dsDNA, although some sera showed rather low titers. In 
both IBT and ENA-CIE, sera were assayed for the presence of anti-RNP, 
anti-Sm and anti-SSB. It should be noted that a lot of sera, designa­
ted as negative in the IBT, do stain bands in the immunoblot; yet, 
these are of (until now) undefined specificities (see for instance 
lanes 10 and 11 in Fig. 1). We observed that both IBT- and CIE-posi-
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tive sera had higher anti-dsDNA titers than sera negative in these two 
assays. The mean anti-dsDNA titer of IBT-positive sera was 1/320, of 
IBT-negative sera 1/172; for CIE-positive sera we found a mean anti-ds­
DNA titer of 1/508 against 1/158 for CIE-negative sera. In Fig. 2, a 
cumulative percentage of IBT-positive and CIE-positive sera was plotted 
as a function of the anti-dsDNA titer. As can be read from the figure, 
more sera tended to be positive in either assay as anti-dsDNA titers 
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Fig. 1 - Immunoblot using various dilutions of sera in our specially 
developed blotting incubator. Lane 1 and 15-17: normal control sera (di­
luted 1/50). Lane 2-5: serum A (serially diluted 1/50 - 1/3200) con­
taining anti-Sm (staining BB'and D ) , anti-RNP (staining a 70-kD band), 
anti-Scl 86, and anti-SSB (staining a 54-kD band). Lane 6-9: serum B, 
serially diluted 1/50 - 1/3200, containing anti-SSB. Lane 10-11: serum 
C, diluted 1/50 and 1/100, containing anti-Scl 86 and staining BB' of 
Sm. Lane 12-14: serum D, serially diluted 1/50-1/800, containing anti-
RNP. 
Note the staining of histone bands HI (especially serum A ) , H2A (most 
sera) and H3 (serum Β), which is partly due to non-specific interaction 
between histones and the conjugate used. 
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increased. This correlates with our previous findings that -in longi­
tudinal studies of patients- ANA titers fluctuate together with anti-
dsDNA titers (17). The IBT seemed to be more sensitive than the CIE-
method: it detected the 3 ANA specificities studied in a higher per­
centage of the sera, and already at lower anti-dsDNA levels. 
Comparison of IBT and CIE with respect to the incidence of anti-RNP, 
anti-Sm and anti-SSB. In Table 1, data on the incidences of anti-RNP, 
anti-Sm and anti-SSB as detected by IBT and CIE in 77 SLE sera have 
been summarized. All six sera that were found anti-RNP-positive by 
IBT were also positive by CIE, but five sera that were anti-RNP-posi-
σι 
ra 
*-> 
с 
α> 
<_> 
ι_ 
cu 
о. 
<υ 
> 
со 
3 
с_> 
50 
Ц0 . 
30 
20 
10 • 
* 
ю 40 160 еад 2560 10210 
anti-dsDNA (titer-1) 
Fig. 2 - Cumulative percentage of IBT-positive (·-·) and CIE-positive 
(•-•) sera, as a function of their anti-dsDNA titer. 
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Table 1. 77 SLE sera tested in IBT and CIE for anti-RNP, anti-Sm and 
anti-SS-B antibodies. Number of sera reacting positive/nega-
tive in the relevant assay. 
Antibody specificity 
+ 
CIE 
IBT + 
6 
0 
RKP 
-
5 
66 
+ 
2 
20 
Sm 
-
4 
51 
SS-B 
+ 
6 6 
2 63 
tive by CIE were found negative by IBT. With respect to anti-SSB anti-
bodies, the results we obtained were comparable: six out of eight sera 
found positive by IBT were also positive by CIE, whereas an additional 
six sera were found positive by CIE only. Obtained results were quite 
different for antibodies to Sm: with the IBT, anti-Sm was detected in 
much more patients' sera than with the CIE: 22 samples were positive 
with the IBT but only two with the CIE. 
From these results, we conclude that the higher sensitivity of the IBT 
compared to the CIE is merely due to a better detection of anti-Sm anti-
bodies. Antibodies to RNP and SSB appear to be better detected by CIE 
than by IBT. 
Relation between IBT and CIE results and clinical manifestations of SLE. 
To relate the incidences of anti-RNP, anti-Sm and anti-SSB with speci-
fic clinical manifestations of SLE, patients were grouped according to 
the major symptoms of disease they displayed during their exacerbation. 
Most of the 77 patients of course showed several major symptoms, and 
can be found in more than one group. Cutaneous and hematological dis-
orders were most frequently seen (in 50-60% of the patients). Fourty 
five per cent of the patients had symptoms of central nervous system 
(CNS) or pulmonary involvement. Only 5 patients (6%) suffered from a 
single symptomatic exacerbation (two patients had renal involvement, 
one skin, and two pulmonary involvements). Tables 2 and 3 show corre-
lations of disease symptoms and results obtained with CIE and IBT. 
Table 2 does this from the point of view of antibody specificity: the 
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Table 2. Relation between studied ANA specificities and major disease 
symptoms. 
Major disease Total number Percentage of sera positive for studied 
feature (%) of patients antibody specificity with mentioned 
(n=77) technique 
RNP Sm SS-B 
CNS involvement 
Renal involvement 
Cutaneous disorders 
Pulmonary involve­
ment 
Hematological dis­
orders 
17 
35 
42 
21 
46 
(22%) 
(45%) 
(55%) 
(27%) 
(60%) 
IBT 
(n=6) 
33%! 
0%2 
66% 
17% 
50% 
CIE 
(n=U) 
18%1 
18% 3 
55% 
18% 
55% 
IBT 
(n=22) 
18% 
50% 
59% 
18% 
41% 3 
CIE 
(n=6) 
0% 
33% 
83% 
50% 
83% 
IBT 
(n=8) 
13% 
88% 2 
50% 
25% 
75% 
CIE 
(n=12) 
0%3 
67% 
75% 
33% 
75% 
1i.e. 33% of the RNP-positive patients as measured by IBT and 18% of 
the RNP-positive patients as measured by CIE showed CNS involvement. 
2p<0.025. 
3p<0.050. 
fraction of sera positive in a test that correlated with a certain dis­
ease symptom of the patient. 
Table 3 shows these correlations from the point of view of disease 
symptom: the fraction of patients with a disease symptom that contained 
a certain antibody specificity in the circulation. Patients with anti-
RNP antibodies showed a decreased frequency of renal involvement, con­
sistently found with both assays. Measured with the IBT, 0% of the 
anti-RNP-positive patients had renal involvement (χ2 = 5.42, p<0.025), 
measured with the CIE, 18% of the anti-RNP-positive patients had such 
disease features (χ2 = 3.85, p<0.050), whereas 45% of the total number 
of patients had symptoms of kidney disease. 
Measured with the IBT, the incidence of anti-SS-B was markedly increa­
sed in patients with renal involvement (88% versus 45% in the total 
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Table 3. Relation between disease symptoms and ANA specificities. 
ANA Assay Total number Percentage of sera with specificied disease 
feature 
speci-
ficity 
(%) of pa- CNS renal cutané- pulmo- hemato-
tients invol- invol- ous dis- nary logical 
vement vement orders invol- disorders 
(n=77) 
vement 
(n=17) (n=35) (n=42) (n=21) (n=46) 
RNP 
Sm 
SS-B 
IBT 
CIE 
IBT 
CIE 
IBT 
CIE 
6 ( 8%) 
11 (U%) 
22 (29%) 
6 ( 8%) 
8 (10%) 
12 (16%) 
12%* 
12% 
24% 
0% 
6% 
o%3 
0%2 
6%3 
31% 
6% 
20%2 
23% 
10% 
14% 
31% 
12% 
10% 
21% 
5% 
10% 
19% 
14% 
10% 
19% 
7% 
13% 
20%3 
11% 
13% 
20% 
1i.e. 12% of the patients with CNS involvement had antibodies to RNP 
demonstrable with the IBT. 
2p<0.025. 
3p<0.050. 
population; p<0.025 by chi-square analysis). A tendency towards the 
same correlation was found with the CIE, but did not reach the 95% con-
fidence limit (χ2 = 2.58). The frequency of anti-Sm was significantly 
decreased in patients with hematological disorders if measured with the 
IBT (χ2 = 4.54; p<0.05), but was found within the limits of a normal 
distribution if measured with the CIE (χ2 = 1.51, not significant). Fi­
nally, the incidence of anti-SS-B was found to be decreased in patients 
with central nervous system involvement if measured with the CIE (χ2 = 
4.03;p<0.05), but normally distributed if measured with the IBT (χ2 = 
0.48). 
DISCUSSION 
In this paper, we have compared the IBT and the CIE with respect to the 
detection of anti-Sm, anti-RNP and anti-SSB. Both assays were performed 
as they have been advocated, i.e. in the IBT we used a nuclear extract 
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of HeLa cells as antigen, in the CIE a salt extract of a (commercially 
available) acetone extract of rabbit thymus. Although this admittedly 
introduces discrepancies based on the source of antigen, we have not 
sought to compare different antigenic preparations in both assays, but 
rather wanted to compare the assays as they are generally used. This 
also implies that we did not use IBT-defined reference sera in the CIE, 
but performed the latter assay in the classical way, i.e. using CDC re-
ference sera to confirm specificities. 
Both with the IBT and the CIE we observed a correlation between the 
incidence of positive results and the mean anti-dsDNA titer. Also, 
when we tested longitudinal series of serum samples of patients, we 
found a rise and fall of anti-RNP and anti-Sm antibodies, accompanying 
titer changes in anti-dsDNA (to be published separately). 
With respect to detection of anti-RNP and anti-SSB, we found that most 
sera positive with the IBT were also positive with the CIE. On the 
other hand, both antibody specificities were detected more frequently 
with the CIE than with the IBT (anti-RNP: 14% versus 8%; anti-SS-B: 
16% versus 10% of the sera respectively). In contrast, anti-Sm was 
detected with the IBT at much higher frequencies than with the CIE 
(29% versus 8% of the patients' sera, respectively). Because discre-
pancies between the IBT and the CIE seem to go both ways, it is not 
easily determined if one assay is more sensitive than the other. With 
respect to the detection of anti-RNP and anti-SSB, it might be that the 
followed protocol of specificity confirmation in the CIE introduced 
false-positive results, as CDC reference sera are often found to con-
tain more than one ANA specificity. 
Another, probably better explanation is that antigenic determinants 
that depend heavily on the tertiary structure of RNP and SSB may be 
destroyed after SDS-PAGE and blotting; this would render the CIE more 
sensitive than the IBT. Discrepant results concerning the detection of 
anti-Sm may be due to the lower concentration of Sm (especially of the 
BB' protein) in rabbit thymus powder. 
Reports in which CIE and IBT were compared with respect to ANA detec-
tion have been published by Habets et al. (18) and Williams et al. (19). 
The former group reported a good correlation between the IBT and the 
CIE with respect to anti-RNP detection, but they selected their sera 
using the IBT and tested them afterwards with the CIE. The latter group 
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found a good correlation between the two assay systems for the detec-
tion of anti-RNP and anti-Sm, but, contrary to our findings, mentioned 
a much better detection of anti-SSB with the IBT than with the CIE 
(18% versus 5% of the SLE patients, respectively). Their conclusion 
that anti-SSB antibodies poorly form precipitines in gel is clearly in 
contrast with our findings. The frequency at which we found anti-RNP, 
especially when using the IBT, is rather low if compared with reviewed 
previous studies (4) or with the study of Williams et al. (19) (this 
paper: IBT, 8%; CIE, 14% of the patients; Williams et al. (19): IBT, 
27%; CIE, 26% of the patients; our literature review (4): 34%). On the 
other hand, the incidence of anti-SSB we found is somewhat increased if 
compared with published figures (this paper: IBT, 10%; CIE, 16% of the 
patients; Williams et al. (19): IBT, 18%; CIE, 5% of the patients; our 
review (4): 5% of the patients). The frequency of anti-Sm determined 
by CIE reported here is lower than mentioned in literature (Smeenk et 
al. (4): 23%; Williams et al. (19): 26%). 
Studies regarding frequencies of ANA specificities are -of course- dif-
ficult to compare, due to different criteria used for the selection of 
patients' sera, and technical differences. The literature we reviewed 
before (4) did not incorporate any frequency study performed with the 
IBT. The recently published study of Williams et al. (19) is also not 
completely comparable with our study. 
Whereas we used a nuclear extract of HeLa cells as antigen, they used 
affinity purified Sm, RNP and SSB. This probably results in much higher 
concentrations of these antigens on the blot, leading to the observed 
higher incidences of anti-RNP and anti-SSB. It does, however, not ex-
plain the rather large discrepancy seen for anti-Sm frequencies (our 
study: 29%; Williams et al.: 17%). 
With respect to relations between incidences of measured antibody spe-
cificities and disease features, we observed several significant corre-
lations: the presence of anti-RNP was negatively correlated with ne-
phritis, both if measured with the IBT or the CIE, in accord with the 
initial report of Reichlin and Mattioli (20). Other significant corre-
lations occurred in one assay only. The prevalence of anti-Sm was de-
creased in patients with hematological disorders only if measured with 
the IBT; if measured with the CIE, however, this prevalence tended to 
be increased compared with the total group. The latter correlates with 
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the literature (21), the former is in contrast with these reports. At 
the moment, we can only explain this on the basis of the observation 
that IBT detects anti-Sm in much more sera than CIE does. Anti-SSB was 
positively correlated with renal involvement if measured with the IBT 
and negatively correlated with CNS involvement if measured with the CIE. 
Previous reports mentioned a decreased incidence of renal involvement 
in patients with anti-SSB (22,23), in contrast with our findings with 
the IBT. These differences probably depend on the selection of patients. 
Wasicek et al. (22) excluded patients with anti-Sm or anti-RNP from 
their study, which we did not and, may be more importantly, the anti-
SSB-positive, but anti-SSA-negative patients studied by Venables et 
al. (23) did not have anti-DNA in their circulation, whereas we select-
ed sera of patients that also contained antibodies to DNA. The associa-
tion we found between renal involvement and the presence of anti-SSB 
may, therefore, be only secondary: our anti-SSB-positive patients gene-
rally had higher titers of anti-DNA than our anti-SSB-negative patients, 
and it is generally known that patients with nephritis tend to have 
high levels of anti-DNA in the circulation. 
Studies concerning clinical correlations of defined ANA are of course 
hampered by the finding that patients may have more than one antibody 
specificity in their circulation. Indeed, the whole concept of subdi-
viding patients on the basis of the presence or absence of certain de-
fined ANA may be questionable, as antibody levels fluctuate, and a pa-
tient that is positive for anti-RNP today may be anti-RNP-negative at 
the next investigation. On the other hand, especially if presented as 
in Table 2, frequencies at which certain ANA occur together with cer-
tain disease features may give us some information on the prognosis of 
the disease. Further studies are needed, however, to solve the matter. 
Higher numbers of available patients' sera will also allow the study of 
potential relationships between clinical features and combinations of 
several defined ANA. 
In conclusion, the IBT and CIE showed different results for the three 
antibody specificities tested. On the one hand, a higher sensitivity 
for anti-Sm was observed, on the other, anti-SSB and anti-RNP could 
often be detected by the CIE but not by the IBT. Although the IBT has 
the advantage of allowing the simultaneous detection of several auto-
antibodies in one lane of electrophoretically separated nuclear antigen, 
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its routine use is hampered by the fact that anti-RNP and anti-SSB seem 
to be better detected by the CIE. However, the deciphering of new anti-
body specificities in the near future will undoubtedly lead to increa-
sed use and usefulness of this technique. 
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SUMMARY 
We compared the classical immunofluorescence test (IFT) and counter-
immunoelectrophoresis method (CIE) with the new immunoblotting tech-
nique (IBT) as assays for the detection of antinuclear antibodies (ANA). 
Sera from 200 patients were tested in all three assays. Patients were 
classified as having either rheumatic disease (RA, SLE, MCTD or primary 
Raynaud's phenomenon) or nonrheumatic disease. With regard to these 
broad categories, we observed that the IFT and IBT showed a more or 
less comparable sensitivity and specificity (IFT: 0.54 and 0.82, respec-
tively; IBT: 0.39 and 0.79, respectively). The CIE method combines a 
high specificity (0.99) with an extremely low sensitivity (0.08). By 
combining positive results obtained by IFT and IBT, a higher specifici-
ty (0.97) but a diminished sensitivity (0.24) is obtained. As the IBT 
allows simultaneous discrimination between ANA of different specifici-
ties, we also tested for a correlation between the presence of anti-Sm, 
anti-RNP and anti-SS-B and disease category. Only anti-SS-B discrimi-
nated significantly between rheumatic- and nonrheumatic disease. Anti-
RNP was found in 50% of the SLE patients and in 50% of the MCTD pa-
tients; anti-Sm in 17% of the SLE patients and 25% of the MCTD patients. 
Anti-SS-B was found in 33% of the SLE patients. However, predictive 
rates of these ANA were low: 0.37 (anti-RNP), 0.67 (anti-Sm) and 0.43 
(anti-SS-B). We conclude that, to screen for the presence of ANA, the 
IFT is the preferable assay from a practical point of view. To charac-
terize ANA specificities, however, the IBT is far superior to the CIE 
technique. 
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INTRODUCTION 
Since the initial description of the LE cell-test by Margraves et ai. 
(1), detection of antinuclear antibodies (ANA) has become of great help 
in problems related to diagnosis and classification of patients with 
rheumatic diseases. The presence of ANA in sera of patients, and also 
in animal models, is correlated with many autoimmune phenomena (2,3). 
Most assays for ANA employ tissue sections of animal origin or cell 
lines as substrate in an indirect immunofluorescence test (IFT). Early 
observers were impressed by distinct IFT patterns seen with different 
sera. Efforts to correlate specific patterns with certain disease en-
tities have not been entirely unsuccesful, but the development of new 
immunoassays has allowed a more precise determination of ANA specifici-
ties. Apart from the classical IFT, agglutination assays, immunodif-
fusion tests, enzyme immunoassays and radioimmunoassays have been de-
veloped in which different sources of antigenic material are used. The 
closest disease correlation is seen between the presence of antibodies 
against double-stranded DNA (dsDNA) and Systemic Lupus Erythematosus 
(SLE), but other less firm correlations have also been described. A 
certain ANA may be described as specific for certain diseases (e.g. 
anti-Sm antibodies for SLE), but this by no means implies that this par-
ticular disease is always accompanied by that specific antibody. Also, 
a defined ANA may be found in patients with different rheumatic dis-
eases . 
In the past few years, a novel biochemical technique has been introdu-
ced in the serology of autoimmune diseases. Immunoblotting with nuclear 
antigens has proven to be of great value in the identification of nu-
clear antigens and ANA (4-5). Some reports have now been published 
that describe relations of defined ANA determined with the immunoblot 
test (IBT), and SLE (6-7), Sjogren's Syndrome (8), scleroderma (9-11) 
and Mixed Connective Tissue Disease (MCTD) (6). 
The question whether this assay adds new information to the classical 
assays mentioned above can be studied from different points of view. 
One can select a certain patient group with well-defined disease symp-
toms or a common diagnosis and study antibody frequencies with the IBT 
as antibody test. As mentioned above, this has been done for many rheu-
matic diseases. The other way of studying ANA is to select sera on the 
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basis of the presence of a particular ANA specificity and correlate 
this with disease manifestations. Both approaches clearly miss the 
point that in daily practice sera are mostly tested from a different 
start: the diagnosis as well as the ANA specificity are not known. Our 
institute has a role as a reference lab for ANA testing, serves as a 
routine lab for a large part of the Netherlands and receives large num-
bers of sera for routine ANA determination. Negative results may en-
courage the physician to exclude certain diagnoses. This implies that 
most of the patients, whose sera are tested and found to be negative, 
will finally have a diagnosis that is not correlated with the presence 
of ANA. 
In this study, we aimed to compare the specificity and sensitivity of 
the (classical) IFT with the IBT in an unselected group of patients' 
sera. We therefore tested 200 sera, sent to our institute for ANA de-
termination, in both assays. All sera were also tested by a counter-
immunoelectrophoresis (CIE), to compare ANA specificities obtained by 
IBT with specificities obtained with the more established CIE. Results 
of all assays were related to clinical data provided by the patients. 
MATERIALS AND METHODS 
Sera. During a period of one week, 600 consecutive sera were collected 
without selection. These sera were sent to our institute for routine 
determination of ANA by an IFT. Part of our institute serves as a rou-
tine and reference centre for autoantibodies for a great part of the 
Netherlands. Sera were sent by general practioners as well as by inter-
nists and rheumatologists. Sera were stored at -20oC before use. 
Clinical data. To obtain clinical information, questionnaires were 
sent to the physicians of the patients from whom serum was collected. 
This questionnaire contained a total of 40 items, mostly in the form of 
questions to be anwered by yes or no. 
The list contained all criteria for rheumatoid arthritis (RA), SLE, 
MCTD and PSS (12-14). Specific questions related to Sjogren's syndrome 
and myositis were also incorporated. Nephrological and haematological 
information as well as additional information, such as biopsy reports 
or correspondence about the patients was requested. Serum from the 
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first 200 patients on whom clinical data became available were tested 
in all three assays. The remaining 400 sera were only tested by IFT 
and CIE. The 200 patients who were studied in detail were divided into 
two broad categories: those with rheumatic diseases and those with non-
rheumatic diseases. Patients were considered to have a rheumatic dis­
ease if they fulfilled the ARA criteria for SLE, RA, MCTD, PSS, Sjo­
gren's syndrome or primary Raynaud's phenomenon (12-14). To serve the 
purposes of this study, the presence of ANA was excluded as a diagnos­
tic criterion. The clinical diagnosis in the 200 patients studied is 
shown in Table 1. 
Table 1. Diagnoses of the 200 studied patients. 
A. Patients with rheumatic diseases 
Diagnosis η 
Rheumatoid Arthritis 32 
Systemic Lupus Erythematosus 6 
Mixed Connective Tissue Disease 4 
I o Raynaud's Phenomenon 8 
Remarks 
B. Patients with nonrheumatic diseases 
Diagnosis 
Arthritis 
Arthrosis 
Polymyalgia-arthralgia 
Skin Diseases 
Infectious diseases 
Malignant Diseases 
Lung Diseases 
Endocrine diseases 
Renal diseases 
Neurological diseases 
Various diagnoses 
η 
9 
10 
25 
33 
17 
10 
5 
3 
8 
3 
27 
Remarks 
(reactive arthritis 5, 
M. Bechterew, 4) 
(Perarthritis humeroscapularis 4, 
arthralgia 11, Polymyalgia 10) 
(Rosacea 7, chronic urticaria 9, 
Excemata 8) 
(Hepatitis В 5, septic arthri­
tis 2) 
(Dysparaproteinemia 2, Lymphoma 
5, Carcinoma 2) 
(Bernier Boeck 1, Pleuritis 4) 
(Hypothyroidism 2, Hyperthyroid­
ism 1) 
(Hypertension 4, Nephritis 4) 
(Anemia 4, raised ESR 1, habi­
tual Abortus 1, general fatigue, 
unexplained fever 21) 
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Antinuclear antibody inmunofluorescence test. Briefly, ANA were deter-
mined by indirect immunofluorescence as described (15). Four-pm cryo-
stat rat liver sections were used as substrate, without fixation. Sera 
were diluted 1:10 in phosphate-buffered saline (PBS, 0.01 M phosphate, 
pH 7.4, 0.14 M NaCl) and incubated for 30 min at room temperature with 
the sections. Bound antibodies were detected with a fluorescein conju-
gated sheep anti-human immunoglobulin antiserum (SH17, prepared in this 
institute). After each incubation, the slides were washed for 30 min 
(3 changes) with barbitene buffer (0.01 M barbitene HCl, pH 7.2; 0.15 M 
NaCl). After the final wash, slides were mounted (with a solution of 
30% glycerol in PBS containing 0.16 mg/ml polyvinyl/alcohol) and read 
in a Leitz Orthoplan microscope with incident illumination. Nuclear 
fluorescence was taken as an indication of the presence of ANA. 
Assay for precipitating antibodies against extractable nuclear antigens. 
Antibodies against extractable nuclear antigens were detected as des-
cribed, using an extract of rabbit thymus powder (Pel Freez, Arkansas) 
as the source of antigen (16). This extract was prepared as described 
by Kurata and Tan (16). Briefly, 1.5 g of rabbit thymus powder was 
mixed for 4 h with 25 ml of PBS at 40C. The mixture was centrifuged 
for 20 min at 20 000 g. The supernatant was recentrifuged once, ali-
quoted and frozen at -70oC. Such preparations contain about 10 mg/ml 
of protein. Glass plates were covered with 1% agarose gels, made in 
electrophoresis buffer (0.05 M barbitone buffer, pH 8.2) containing 
0.01% Thimerosal (Sigma, St. Louis, M0). Holes, 4 mm in diameter, were 
punched 5 mm apart and filled with antigen and serum. Counterimmuno-
electrophoresis (CIE) was carried out with the antigen holes on the 
cathode side at 120 V, 20 mA per plate for about 45 min, or until a 
solution of 0.25 mg/ml of bromophenol blue in electrophoresis buffer 
had run for 1.7 cm. To complete the immunoprecipitation reactions, 
plates were left overnight at room temperature in a wet chamber. After 
extensive washing, first with PBS then with distilled water, plates 
were dried under pressure at 80oC. Precipitation lines were stained 
with a solution of 1% Coomassie Brilliant Blue in fixing solution 
(water:ethanol:acetic acid = 9:9:2). 
Plates were read and confirmation of an observed reactivity as either 
anti-RNP, anti-Sm or anti-SS-B was achieved by: 1) comparison with 
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reference sera (Arthritis Foundation, CDC, Atlanta (17)) where lines of 
complete identity were searched for, and 2) sensitivity of the preci­
pitation reaction to RNase treatment of the antigen. 
Immunoblotting for the detection of antinuclear antibodies. The tech­
nique employed was described earlier (7,18). Briefly, nuclear antigen 
was prepared from HeLa cells collected from liquid culture in a loga­
rithmic growth phase. After washing, cells were lysed in a hypotonic, 
detergent-containing buffer (0.05 M KCl, 0.01 M NaCl, 0.05 M phosphate 
buffer, pH 7.5, 1 mM EDTA and 0.5% (v/v) Nonidet P-40). By shearing 
through a 1.2x40-mm needle, and centrifugation over a sucrose cushion 
(0.8 M sucrose, 0.025 M KCl, 1 mM EDTA, 1% (v/v) Nonidet P-40), a pel­
let of nuclei was obtained. The nuclei were sonicated and after diges­
tion with DNase and RNase, the extract was prepared for electrophoresis 
as described (18). After electrophoresis in SDS Polyacrylamide gels 
(19) and transfer of the nuclear proteins to nitrocellulose (20), blots 
were incubated with patients' sera, in a blotting incubator that allow­
ed simultaneous testing of 21 samples on one blot (18). Sera were dilu­
ted 1:10 in PBS containing 0.1% Tween (PBST) and incubated with the 
blot for 2 h at room temperature. 
After washing with PBST (3 changes of 15 min each), antibodies bound to 
nuclear antigens were detected with a horse-radish peroxidase-conjuga-
ted rabbit anti-human IgG antiserum (Dakopatts, cat. nr. P215), diluted 
in PBST containing 10% normal rabbit serum. Staining of the blots was 
performed with 4-chloro-l-naphthol (Sigma, cat.nr. C8890) as substrate 
(21). Standard sera were applied on each blot as positive controls and 
as reference samples, to allow identification of anti-RNP (Mr 68 band), 
anti-Sm, (Mr 28 doublet, BB', and a Mr 13 band, D) and anti-SS-B (Mr 54 
band). 
Statistics. Data were analyzed with the Statistical Analysis System 
Release 5 (SAS Institute Inc., Cary, NC). Chi-square analysis with 
Yates correction was used for 2 by 2 tables. When expected cell fre­
quencies were less than five, Fisher's exact test was applied. Ρ values 
less than 0.05 were regarded as significant. 
Sensitivity specificity and predictive value of a positive test were 
calculated for separate assays, for combined assay results or for iden-
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tities obtained in one assay (22). 
RESULTS 
Comparison of ANA detection by IFT, IBT and CIE. Sera of 600 patients 
sent to our institute for routine ANA determination were tested by 
means of the IFT. We found 192 sera (32%) to be IFT-positive. Of the 
200 sera tested in all three assays, 54 (27%) were IFT-positive, which 
indicates that the 200 selected sera give a representative picture of 
the 600 initially tested sera. Clinical details of the 200 selected 
patients have been summarized in Table 1. The 200 selected sera were 
also tested by the IBT and the CIE. Using the IBT, we only scored the 
presence of anti-Sm, anti-RNP and anti-SS-B. Fifty two sera contained 
such IBT-detectable antibodies. We observed a relatively small overlap 
between IFT and IBT: only 17 sera were positive in both assays (Table 
2). Only 5 sera were positive by CIE. Four of these were also IFT-
positive, but only 3 were IBT-positive. 
Incidence of ANA in patients with rheumatic disease versus patients 
with nonrheumatic disease. On the basis of the clinical details, the 
patients were divided into two groups: those with rheumatic diseases 
(50 patients) and a group with "nonrheumatic" diseases (150 patients). 
We have related assay results to these broad categories (Table 3) and 
calculated possible statistical correlations (Table 4). From these 
Table 2. Relation between IFT and IBT. 
IBT 
Number of sera reacting 
Assay Result positive negative total 
positive 17 37 54 
IFT 
negative 35 111 146 
total 52 148 200 
Continuity Adj. chi-square = 0.798; ρ = 0.372 (η.s.) 
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Table 3. Relation between assay results and disease spectra. 
Assay 
disease IFT IBT CIE IFT/IBT 
+ - + - + - + -
rheumatic 27 23 20 30 4 46 12 38 
nonrheumatic 27 123 32 118 1 149 5 145 
total 54 146 52 148 5 195 17 183 
tables, it can be seen that all three assays discriminate in a signi­
ficant way between patients with the defined rheumatic diseases and pa­
tients with "nonrheumatic" diseases. However, both the IFT and the IBT 
combine low sensitivity with low specificity (IFT: 0.54 and 0.82, res­
pectively; IBT: 0.38 and 0.79, respectively). Only 50% of the sera 
positive with the IFT and 38% of the sera positive with the IBT came 
from patients with diseases characterized by the presence of ANA (ter­
med "predictive value of a positive test" in Table IV). By combining 
IFT and IBT, the specificity is increased (to 0.97), at the cost of 
sensitivity. The CIE method combines very high specificity with extre­
mely low sensitivity, which completely rules out the use of this tech­
nique in routine ANA screening. 
Table 4. Statistical data on IFT, IBT and CIE obtained by comparison 
of rheumatic patients with nonrheumatic patients. 
Assay χ 2 Ρ sensitivity specificity predictive 
value of a 
positive test 
0.82 0.50 
0.79 0.38 
0.85 0.37 
0.99 0.67 
0.92 0.43 
0.99 0.80 
0.97 0.71 
* 
Fisher's Exact Test was used 
IFT 22.87 
IBT 5.86 
-aRNP 2.60 
* 
-aSm 
-aSSB 3.00 
* 
CIE 
IFT + IBT 
<0.0001 0.54 
<0.016 0.39 
>0.107 0.26 
>0.155 0.04 
<0.046 0.18 
<0.014 0.08 
<0.001 0.24 
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Incidence of ANA in defined disease entities. Of the 50 patients with 
rheumatic diseases, 32 had RA, 6 SLE, 4 MCTD and 8 primary Raynaud's 
phenomenon (Table 1). In Table 5, assay results have been related to 
the various rheumatic diseases in two ways: either starting from the 
diagnosis (columns marked "A")» or starting from the assay result 
(columns marked "B"). Using the former approach, we note the following. 
All of the MCTD patients and all of the SLE patients were found to be 
IFT-positive. In RA and primary Raynaud's phenomenon, the percentages 
of positive sera were lower (44% and 38%, respectively), but still much 
higher than in patients with nonrheumatic diseases. With respect to 
the IBT, we found that all of the MCTD patients were positive, whereas 
50% of the SLE patients, 31% of the RA patients and 38% of the patients 
with primary Raynaud's phenomenon gave a positive reaction in the IBT. 
Although all these percentages were higher than the percentage of pa­
tients with nonrheumatic disease, who gave a positive IBT reaction, 
this increase was only significant for MCTD patients (Fisher's exact 
test, p=0.004). Only 5 sera gave a positive result in the CIE method. 
Fifty percent of the MCTD patients were found positive as well as 33% 
of the SLE patients. All of the patients with RA were found to be CIE-
negative, whereas one patient out of the group of nonrheumatic dis­
eases had CIE-detectable ANA. 
Table 5. Diagnosis and assay results of 200 sera in IFT, IBT and CIE. 
Diagnosis η 
RA 32 
SLE 6 
MCTD 4 
Raynaud's phen. 8 
total rheumatic 
disease 50 
nonrheumatic 
disease 150 
IFT-pos. 
A1 
44 
100 
100 
38 
54 
18 
<%) 
B2 
26 
11 
7 
6 
50 
50 
IBT-pos. 
A1 
31 
50 
100 
38 
40 
21 
(%) 
B 2 
19 
6 
7 
6 
38 
62 
CIE-pos. 
A1 
0 
33 
50 
0 
8 
1 
<%> 
B 2 
0 
40 
40 
0 
80 
20 
1Percentage of patients with the given diagnosis having the ANA indica-
ted in the column; i.e. 44% of the RA patients were IFT-positive. 
'Percentage of the positive sera that come from patients having the 
diagnosis indicated; i.e. 26% of the IFT-positive sera come from pa­
tients with RA. 
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Starting from the assay result (columns marked "B"), which is the ac­
tual way diagnostic assays are generally used, percentages obtained are 
quite different. We now observe that 50% of the sera that are IFT-pos­
itive, 62% of the sera that are IBT-positive and 20% of the sera that 
are CIE-positive come from patients with nonrheumatic diseases. Of the 
remaining IFT-positive sera, 26% came from patients with RA and 11% 
from patients with SLE. For the IBT, these percentages were comparable 
(19% and 6%, respectively). With the CIE method, we found that 40% of 
the positive sera came from patients with SLE and exactly the same per­
centage from patients with MCTD. 
Diagnostic significance of specific ANA. Although we found that for 
purposes of ANA screening, the IFT has a higher sensitivity than the 
IBT, the latter technique offers the advantage of allowing identifica­
tion of the anti-nuclear antibody. In this study, only anti-Sm, anti-
RNP and anti-SS-B were scored, and IBT results related to disease diag­
nosis are presented in Table 6. Again, we presented the results in two 
ways: as a percentage of the patients having the ANA (columns marked 
"A") and as a percentage of the positive ANA coming from patients with 
the indicated disease (columns marked "B"). From the 52 IBT-positive 
sera, 6 showed more than one identity. 
Table 6. IBT results related to disease diagnosis. 
IBT-positive (%) 
Diagnosis η 
32 
6 
4 
8 
RNP 
A1 
19 
50 
50 
25 
B 2 
17 
8 
6 
6 
A1 
0 
17 
25 
0 
Sm 
B8 
0 
33 
33 
0 
SS-B 
A 1 B 2 
16 24 
33 9 
25 5 
13 5 
RA 
SLE 
MCTD 
1° Raynaud's phenomenon 
Total rheuatic disease 50 26 37 4 67 18 43 
Nonrheumatic disease 150 15 63 1 33 8 57 
Percentage of patients with the given diagnosis having the ANA indica­
ted in the column; i.e. 19% of the RA patients had antibodies to RNP 
according to the IBT. 
Percentage of the positive sera that come from patients having the 
diagnosis indicated; i.e. 17% of the anti-RNP-positive sera came from 
patients with RA. 
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Table 7. CIE results related to disease diagnosis. 
Diagnosis 
RA 
SLE 
MCTD 
1° Raynaud's phenomenon 
Total rheumatic 
Nonrheumatic 
diseases 
diseases 
η 
32 
6 
4 
8 
50 
150 
η 
0 
2 
2 
0 
4 
1 
CIE· -positive 
identity 
-
RNP; Sm 
RNP; SS-B 
-
SS-B 
All of these were at the same time anti-RNP- and anti-SS-B-positive, 
one was also anti-Sm-positive. The last mentioned serum came from a 
patient with SLE. Of the remaining 5 patients, 1 had SLE, 1 RA and 3 
had nonrheumatic diseases. It can be observed that only anti-SS-B dis­
criminates significantly between patients with and patients without 
rheumatic diseases (Table A). We found that of the patients with non­
rheumatic diseases, 15% had anti-RNP, 8% anti-SS-B and 1% anti-Sm. How­
ever, starting from the antibody, 63% of the anti-RNP-positive sera, 
33% of the anti-Sm-positive sera and 57% of the anti-SS-B-positive sera 
came from patients with nonrheumatic diseases. 
The CIE method also allows differentiation between anti-Sm, anti-RNP 
and anti-SS-B. However, as only 5 sera gave a positive result with 
this technique, we did not calculate incidences as for the IBT, but in­
stead presented the actual results in Table 7. Comparing IBT with 
CIE, we observed that 2/4 MCTD patients had antibodies to RNP according 
to the IBT, but only 1 according to the CIE. Of the patients with SLE, 
3/6 had IBT-detectable anti-RNP, but only 1 had CIE-detectable anti-RNP. 
DISCUSSION 
In this paper, we have presented a comparative study of three techni­
ques used to measure antinuclear antibodies: the immunofluorescence 
test using rat liver sections as substrate, the counterimmunoelectro-
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phoresis method using a commercially available nuclear extract of rab-
bit thymus (Pel Freez) as antigen and the immunoblotting technique 
using a nuclear extract from HeLa cells as antigen. As we especially 
wanted to know the benefit of these techniques for ANA determination in 
routine testing, we did not use groups of defined patients to compare 
the assays but, instead, used sera sent to us for routine ANA determi-
nation. In our view, this relates best to the way such assays are 
likely to be used. Clinical data on the patients were obtained by 
questionnaires. It is our experience that reliable information can be 
obtained in this way (23). All information obtained was summarized by 
A.J.G. Swaak and diagnosis was made based on the defined ARA criteria 
without prior knowledge of the ANA results. 
We found that all three assays differentiate significantly between 
patients with and without rheumatic diseases. However, as most sera 
did not come from patients with rheumatic diseases, a positive assay 
result only has a predictive value of 50% (IFT), 38% (IBT) or 80% (CIE). 
Comparison of IFT and IBT led to the conclusion that the former has a 
somewhat higher sensitivity and specificity with regard to rheumatic 
diseases (0.54 and 0.82 versus 0.39 and 0.79 for the IBT). Also, the 
overlap between both assays is not very high. Therefore, the use of 
the IFT as a screening assay for ANA has some advantages over the IBT, 
although it would probably be best to use both assays simultaneously. 
The CIE method has such a low sensitivity that this technique is of no 
value in ANA screening. 
Dividing the patients with rheumatic diseases into 4 different groups 
(RA, SLE, MCTD and primary Raynaud's phenomenon), we observed the fol-
lowing. The incidences of IFT-detectable ANA in the various disease 
groups are quite comparable to those reported in literature (2,24-26). 
With respect to the IBT, such incidences have not yet been published. 
A comparison between IFT, IBT and CIE does not show great differences 
between these techniques with regard to ANA incidences measured in the 
various groups (columns marked "A" in Tables 5 and 6). 
As the assays are most likely to be used without prior knowledge of the 
disease of the patient, we think that the columns marked "B" provide 
more useful information than those marked "A". Columns marked "B" tell 
us which percentage of the positive sera can be related to a certain 
diagnosis. Clearly, a positive assay result does not directly indicate 
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that the patient has a rheumatic disease, let alone which rheumatic 
disease. So, although all 4 MCTD patients were IFT-positive, a positi-
ve IFT result could in only 7% of the cases be related to a patient 
with MCTD. 
A clear advantage of IBT and CIE over IFT is that these techniques 
allow (some form of) identification of the detected ANA. In the CIE-
method, reference sera are used to identify anti-Sm, anti-RNP and anti-
SS-B. Although the IBT allows the identification of more than these 
three ANA systems, we only looked at these in the study presented here. 
As only 5 sera had CIE-detectable ANA, it is difficult to relate CIE-
detectable ANA incidences to the various diseases. It would seem that 
the incidences of anti-Sm and anti-SS-B are comparable to what has been 
described in literature, whereas anti-RNP was found less frequently 
than described. For instance, we observed that only one of the 4 MCTD 
patients had CIE-detectable anti-RNP. Looking at the IBT results, we 
observe incidences of anti-Sm comparable to what has been published 
(26), whereas anti-RNP and anti-SS-B seem to occur at somewhat higher 
frequencies than described (25,26). In fact, we found a basic frequen-
cy of anti-RNP and anti-SS-B of about 15% and 8%, respectively, in pa-
tients with a nonrheumatic disease. For comparison: in normal donors, 
these incidences are less than 1% (data not shown). 
In conclusion, we found that IFT and IBT have more or less comparable 
sensitivities and specificities with respect to routine ANA screening, 
the IFT being slightly in the advantage. The CIE method has a sensiti-
vity that is too low to be useful in ANA screening. Therefore, if one 
only desires to know whether ANA are present, the IFT may be the prefer-
red assay. However, the IBT allows the simultaneous identification of 
ANA, with a much higher sensitivity than the (traditional) CIE method. 
In this study, we focussed our attention on anti-Sm, anti-RNP and anti-
SS-B only. It is to be expected that inclusion of other ANA systems 
(anti-Jo-1, anti-Scl86, anti-centromere, anti-SS-A and other yet un-
known ANA) will lead to an ever higher sensitivity of the assay. There-
fore, it is probably advisable to use both assays simultaneously when 
screening for the presence of ANA. 
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SUMMARY 
The specificity of antiperinuclear factor (APF) for patients with rheu-
matoid arthritis (RA) is well documented. The question whether detec-
tion of these antibodies adds information to the detection of rheuma-
toid factor (RF) has not yet been answered. In a group of 132 patients 
with RA, 94 were RF positive. Of the 38 patients persistently negative 
for RF, 14 (37%) were positive for APF. These 14 patients proved to 
have a disease course similar to that of RF-positive patients. This si-
milarity was most impressively shown by radiological progression of the 
disease and to a lesser extent by the medication needed to control the 
disease and the number of extra-articular manifestations. No signifi-
cant correlation was shown between APF and antinuclear antibodies. 
Among the RF positive patients with their generally poorer prognosis, 
APF identified those which were worst off. This study suggests that APF 
in serum of patients with RA is associated with a worser outcome of the 
disease, especially in the RF negative patients. 
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INTRODUCTION 
Antiperinuclear factor is an antibody that binds with granules situated 
around the nuclei of human buccal mucosa cells. The presence of this 
antibody was originally described by Nienhuis and Mandema in 1964 (1). 
Testing patients' sera for antinuclear antibodies with human buccal mu-
cosa cells as substrate , they observed a typical cytoplasmic fluor-
escence of perinuclear granules. Nearly all the sera with this fluor-
escence pattern were from patients with rheumatoid arthritis. Very few 
of the sera from patients with other rheumatic diseases were positive. 
The specificity was high, but the sensitivity proved to be low, only 
some 50% of the patients with rheumatoid arthritis being positive. The 
diagnostic value of this antibody assay has been confirmed by others 
(2,3). Presence or absence of this antibody has been correlated with 
the degree of disease activity, but these data are conflicting (1,2). 
The antigen is yet to be characterized (4 ) and the pathogenetic role 
therefore cannot even be speculated on. A certain overlap with antike-
ratin antibodies exists (5,6). 
The aim of our study was to establish whether the antiperinuclear fac-
tor, measured in sera of patients with rheumatoid arthritis, has any 
relation with the course of the disease. We therefore studied a group 
of rheumatoid arthritis patients, seropositive as well as seronegative. 
Our report is concerned with two main points : 1. An evaluation of 
known parameters of severity of disease: ARA functional class, extra-
articular manifestations and therapy with disease modifying drugs. 2. 
A radiological survey of the progression of joint involvement. Both 
subjects were studied in connection with the presence or absence of 
rheumatoid factor and antiperinuclear factor. Because a cross reaction 
of some rheumatoid factors and nuclear antigens and a correlation be-
tween antinuclear antibodies and severity of rheumatoid arthritis has 
been described (7,8), we also studied antinuclear antibodies in our pa-
tients. Correlations between rheumatoid factor, antiperinuclear factor 
and antinuclear antibodies were studied. 
MATERIALS AND METHODS 
Patients and controls. Patients with classical or definite rheumatoid 
73 
arthritis (RA) according to the American Rheumatism Association crite-
ria (9) and with a disease duration of at least three years were stu-
died. All RA patients satisfying the abovementioned criteria and atten-
ding the out-patient clinic of the department of rheumatology during a 
period of three months, entered the study. Because the number of per-
sistently seronegative (as defined below) patients was too small after 
these three months, we included all seronegative RA patients attending 
the out-patient clinic during a consecutive period of six months. Pa-
tients were examined to exclude other rheumatic diseases (systemic lu-
pus erythematosus, psoriatic arthritis, seronegative spondylarthro-
pathy, degenerative joint disease). A total of 132 patients included 96 
females and 36 males. Serum samples of 54 healthy blood donors (34 fe-
male, 20 male) were tested for antiperinuclear factor (APF). Mean age 
of these donors was 35.2 years. 
Clinical and serological assessment. In these patients the ARA functio-
nal class (10) was estimated at the moment of study and the extra-arti-
cular manifestations (EAM) of the disease were recorded: those present 
at the moment of study and those mentioned in the medical records. Al 
patients with complaints of dry eyes and dry mouth had a Schirmer test 
done and were examined for keratoconjunctivitis by an ophtalmologist. 
The diagnosis Sicca syndrome was based on at least complaints and a po-
sitive Schirmer test. Complaints of neuropathy were always verified by 
physical examination and by electromyography observation. The informa-
tion on corticosteroids and on slow-acting antirheumatic drugs 
(SAARD's) used by the patients from the moment of onset of disease un-
til! the time of the study was obtained from medical records. The num-
ber of arthroplasties was scored for each patient. All patients were 
HLA typed for HLA-B27. 
Rheumatoid factor. Sera were tested for rheumatoid factor (RF) using 
the Waaler/Rose test (WRT) and the latex fixation test (LFT). These ag-
glutination assays were performed as a microtitre modification (11) of 
the technique described earlier (12). RF was determined at least three 
times at different moments during the course of the disease with a mi-
nimal interval of at least one year. Many patients had more serum sam-
ples tested for RF. All patients that were regarded as RF negative 
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(RF-)/ had at the maximum two samples that reached a titre of 1:64 or 
1:80 in WRT or LFT; all other samples during the course of the disease 
had lower titres or were completely negative. 
Antiperinuclear factor. APF was determined as described earlier (1,3). 
In essence the procedure was the following: human buccal mucosa cells 
were obtained by scraping the inner side of both cheeks of a healthy 
human donor with a piece of plastic foam. The foam was rinsed in phos­
phate buffered saline (10mM phosphate buffer pH 7.4, 140 mM NaCl, PBS). 
Cells were washed three times in PBS and spun down on microscope slides 
with a cytospin centrifuge. All procedures were carried out at room 
temperature. After drying for 15 minutes the cell preparations were in­
cubated for 90 minutes with undiluted sera. After washing with three 
changes of PBS for 30 minutes, the slides were incubated for 30 minutes 
with a fluorescein isothiocyanate (FITC) conjugated sheep antiserum 
against human immunoglobulin (Central Laboratory, Red Cross Blood 
Transfusion Service, Amsterdam, Cat.no. M1094). This antiserum has a 
molecular F/P ratio of 2.9. After another washing with PBS for 3 χ 10 
minutes slides were mounted with PBS-glycerol (1:1) containing ethidium 
bromide at a final concentration of 0.5 >ig/ml. Slides were read under a 
Leitz Ortholux II fluorescence microscope. Fluorescence of homogeneous 
spheres around the nucleus was taken as the presence of APF. Fluor­
escence was scored in 5 categories according to Marmont (2), ranging 
from from О to +++. Patients were classified as APF positive (APF+) 
when there was at least one serum sample with ++ or +++ APF or two dif­
ferent serum samples obtained with at least one year interval with + 
APF. Other patients were recorded as APF negative (APF-). 
Antinuclear antibodies. Sera were tested for antinuclear antibodies 
(ANA) with 4 ym cryostate sections of rat liver as substrate. Sections 
were used unfixed. Sera were diluted 1:10 in PBS and incubated for 30 
minutes. The same FITC conjugated antiserum was employed as was used 
for APF determination. Washings after incubations were for 3 χ 10 mi­
nutes. Patients were regarded as ANA positive (ANA-)-) when two different 
serum samples (taken with at least a one year interval) were positive 
when assayed for ANA. 
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Radiographs. Plain anterior posterior radiographs of both hands, wrists 
and feet were used to score joint involvement. Patients were scored (as 
much as possible) 3,10 and 15 years after onset of the RA. The radio­
graphs were read and graded independently by two observers (AB, MJ) 
using standard radiographs of Lar sen (13) as a reference. When there 
was disagreement about the radiological destructions, a final score was 
reached in a combined session. The Larsen index was calculated as fol­
lows. Each proximal interphalangeal, metacarpophalangeal and metatarso­
phalangeal joint, and the wrist, was graded on a scale from zero to 
five. The score of the wrist was multiplied by five. The total score of 
the joints mentioned is the Larsen score we used. All joints operated 
on (except synovectomy) were scored as three. 
Statistical Analysis. Data were analysed with the Statistical Analysis 
System, release 5.16 (14). Sex ratios and EAM were analysed by Chi-
square analysis. Means of disease duration were tested with the t test 
for the comparison of two independent means. APF, RF and ANA were ana­
lysed by Chi-square statistics for 2 x 2 tables with Yates continuity 
correction; Fisher's exact test was used when expected frequencies were 
less than five. Larsen scores and ARA functional class were tested with 
the Kruskal-Wallis test (Chi-square approximation with df = 3 ) . When a 
level of significance of less than 0.05 was reached, two groups were 
compared by means of the Wilcoxon Rank sum test for two independent 
samples. Ρ values were regarded as significant when less than 0.05. 
RESULTS 
The 132 patients studied were divided into four groups. RF- and APF-po­
sitive (RF+/APF+); RF-positive, APF-negative (RF+/APF-)? RF-negative 
and APF-positive (RF-/APF+); negative in both assays (RF-/APF-) (table 
1 ). Results of sero-surveys and correlations between RF, APF and ANA 
are given in table 2. Ninety-four of the total of 132 patients were RF-
positive (71%). The frequency of the APF in the 38 RF-negative patients 
was 37% (14/38). The fraction of patients positive in either one of the 
assays was 82%. ANA were present in 59 of the 132 patients (45%). Al­
though RF correlates with both ANA and APF, the correlation with the 
former is much better than that with the latter. APF and ANA were not 
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Table 1. Demographic and clinical characteristics of the four groups of 
RA patients. 
number of patients 
sex* (female/male) 
age* (years) 
mean 
range 
disease duration* (years) 
mean 
range 
functional class (%) 
I 
II 
III 
IV 
antinuclear antibody (%) 
previous hip, knee, ankle 
or shoulder arthroplasty (%) 
Rheumatoid factor/Ant 
+/+ 
55 
2.2 
56 
36-82 
14.7 
4-32 
7 
62 
29 
2 
51 
61 
+/-
39 
3.9 
56 
35-80 
15.8 
3-32 
31 
67 
2 
0 
62 
22 
iperinuclear 
-A 
14 
2.5 
51 
28-69 
11.8 
3-28 
50 
36 
14 
0 
14 
13 
factor 
-/-
24 
2.4 
60 
29-83 
11.8 
3-31 
67 
33 
0 
0 
21 
10 
* sex, age and disease duration did not differ significantly in the 
four groupa. 
correlated. In the 38 RF negative patients ANA and APF were also not 
related (P = 0.483). From 50 control sera of healthy bloeddonors, two 
(4%) were RF-positive and only one (2%) was APF positive. All patients 
could easily be attributed a "positive" or "negative" mark for the 
three antibody specificities, because when scored as positive for a 
certain antibody, they had at least two serum samples positive for that 
antibody. 
The functional class of the patients is given in table 1. The median 
ARA functional class was II, II, II/I and I for the respective groups. 
Patients in the RF+/APF+ group were significantly more likely to have a 
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Table 2. Relations between rheumatoid factor, antiperinuclear factor 
and antinuclear factor in RA patients. 
APP 
Chi-
square 
+ 
-
RF 
+ 
55 14 
39 24 
4.26 
ANA 
+ 
-
RF 
+ 
52 7 
42 31 
13.45 
ANA 
+ 
-
APF 
+ 
30 29 
39 34 
0.014 
= 0.04 < 0.001 N.S. 
Table 3. Number of extra-articular manifestations of rheumatoid 
arthritis in four patient groups. 
Rheumatoid factor/Antiperinuclear factor 
+/+ +/- -/+ -/-
number of patients 55 39 14 24 
nodules 
Sicca syndrome 
neuropathy 
splenomegaly 
ulcera 
nailfold lesions 
33(60%) 
4 
5 
1 
5 
3 
16(41%) 
3 
1 
1 
4*(29%) 
1 
1 
4*(17%) 
EAM per patient 0.93 0.54 0.43 0.17 
EAM = extra-articular manifestations. 
* Ρ = 0.01 for RF-/APF+ and RF-/APF- versus RF+/APF+. 
higher functional class than those in the other three groups (P <0.05). 
The RF-/APF- patients never had ARA functional class III or IV. The 
number of EAM is documented in table 3. The number of EAM per patient 
was largest in both RF+ groups (0.93 and 0.54). Both RF negative groups 
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had a smaller mean number of EAM, of these two groups, APF+ were 
slightly more affected with EAM (0.43) than APF- (0.17). Only the num­
ber of patients with subcutaneous nodules allowed statistical analysis: 
nodules were present in a higher frequency in the RF+/APF+ group than 
in both RF-negative groups. The RF+/APF- group did not differ signifi­
cantly from either one of the other patients groups. 
HLA-B27 frequencies in the four patients groups were 9 (RF+/APF+), 13 
(RF+/APF-), 8 (RF-/APF+) and 13 (RF-/APF-) versus 11% in a group of 277 
healthy blood donors. 
The number of drugs prescribed in the four patients groups is given in 
table 4. To facilitate interpretation of these data, we classified the 
five drugs according to their efficacy and toxicity (15), and only ar­
bitrarily assigned a rank number to each of the drugs (table 4). This 
ranking order is equal to the sequential order in which these drugs are 
Table 4. Slow acting antirheumatic drugs in four groups of RA patients. 
Rheumatoid factor/Antiperinuclear factor 
Number of +/+ +/- -/+ -/-
patients 55 39 14 24 
rank 
1 Hydroxychloroquine (Ну) 
2 Aurothioglucose (Au) 49 
2 D-penicillamine (Dp) 
3 Azathioprine (Az) 
3 Cyclophosphamide (Cy) 
Medication index 
All drugs 3.88*(2.63)+ 4.21(2.66) 2.86(2.42) 2.21(1.87) 
Ну., Au., Dp. 3.07(2.09) 3.36(2.13) 2.43(2.06) 1.96(1.66) 
Az., Cy. 0.80(0.55) 0.85(0.54) 0.43(0.36) 0.25(0.21) 
0
 number of patients who received this drug at least for one period 
during the the course of the disease 
* medication index, see section "Results" for explanation 
+ medication index corrected for disease duration (multiplied by 10 and 
divided by mean number of years of disease duration) 
22° 
26 
14 
1 
17 
37 
20 
11 
10 
8 
4 
2 
9 
16 
3 
2 
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used in our clinic. For each group of patients a medication index was 
calculated as follows. The number of patients who received a certain 
drug was multiplied by the rank number. The sura of these products was 
divided by the number of patients in that particular group. This gave 
an overall impression of the intensity of treatment. Consecutively the 
five SAARD's were divided into two groups: hydroxychloroquine, auro-
thioglucose and d-penicillamine as the least toxic drugs and the other 
two as cytotoxic drugs. In this way a differentiation in treatment 
could be made. These numbers are more balanced when the indices are di-
vided by the mean duration of disease (table 4, numbers in parenthe-
ses) . All four groups were treated equally with hydroxychloroquine, 
aurothioglucose and d-penicillamine. RF positive groups were treated 
equally with the cytotoxic drugs, only 8% of RF-/APF- patients and 14% 
of the RF-/APF+ group received these drugs. Oral corticosteroids were 
Table 5. Radiological scores in four patients groups after 
3, 10 and 15 years of disease duration. 
RF/APF* 3 years 10 years 
36 
2-149 
45 
31 
0-95 
33 
38 
0-64 
11 
11.5 
3-25 
12 
15 years 
50 
4-124 
34 
53 
5-106 
28 
38 
19-94 
4 
24 
15-38 
8 
+/+ 
+/-
-/+ 
-/-
median 
range 
number 
median 
range 
number 
median 
range 
number 
median 
range 
number 
12 
0-77 
51 
10 
0-48 
38 
15 
0-35 
14 
9 
0-25 
22 
* RF/APF: results in RF and APF assays. 
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used by 51/ 51, 43 and 25 percent of the four respective patients' 
groups for at least one period during the course of the disease. 
Larsen scores calculated from radiographs after 3,10 and 15 years of 
disease duration are summarized in table 5. Kot all patients had appro­
priate radiographs available, so numbers of patients do not correspond 
completely with the other tables. Analysis of the four groups of pa­
tients showed that group scores differed only after 10 and 15 years 
(Kruskal-Wallis test Ρ = 0.005 and ρ = 0.031 respectively). When the 
RF-/APF+ group is compared with the RF-/APF- group, the Larsen scores 
after 10 years are significant different (Wilcoxon Rank sum test Ρ = 
0.021). The RF-/APF- group also differed from the RF+/APF+ group: after 
10 as well as after 15 years of disease duration (Wilcoxon Rank sum 
test Ρ = 0.0005 and Ρ = 0.0071). Throughout the course of the disease 
the Larsen score in RF-/APF*· patients worsened almost in the same way 
as in both RF-positive groups. After 15 years of disease duration ra­
diographs for calculation of the Larsen score were available for only a 
small number of patients in the RF-negative groups (4 and 8 for RF-/ 
APF+ and RF-/APF- group respectively). The patients that had a complete 
radiological follow-up were not a specific selection of the total study 
population, but the number of observations is too small to reach sta­
tistical significant differences. 
DISCUSSION 
The APF discriminates two distinct groups in a population of RF-negati­
ve patients. One group, the APF positive, with a more severe form of 
the disease: higher ARA functional class, more EAM per patient and a 
more rapid radiological progression than the other group, the APF nega­
tive. In the RF-positive patients the presence of APF showed less im­
pressive correlations with disease severity. RF+/APF+ patients, in com­
parison with the RF+/APF- group,presented with a higher ARA functional 
class and more EAM; their Larsen score and the medication needed to 
control the disease were equal. 
The diagnosis seronegative (RF negative) rheumatoid arthritis remains 
an important point of discussion (16). For several reasons, we feel 
safe in using this diagnosis. Firstly, patients have been observed for 
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at least three years.During these years, and for many patients during a 
longer period, the diagnosis remained unchanged regardless of the nega-
tive RF tests. Secondly, other diagnoses were excluded by careful exa-
mination of the patients. Seronegative spondylarthropathies like anky-
losing spondylitis are unlikely to be present in our patient popul-
ation: frequencies of HIiA-B27 in the four patient groups were the same 
as in our control group. Moreover, from 34 out of 38 RF negative pa-
tients radiographs of the pelvis and/or sacroiliac joints were avai-
lable. Only one was diagnosed as a possible bilateral sacroiliitis; the 
patient was negative for HLA-B27. Thirdly,radiological changes in both 
groups (RF positive as well as RF negative) were typical of those ob-
served in patients with RA. We therefore concluded that the RF-negative 
patients in this study really suffered from RA. 
We used quite high titres for differentiating seronegative from seropo-
sitive patients because seroconversion is reported to occur more fre-
quently when discriminating at lower titres (17). Moreover, the longi-
tudinal way we evaluated our patients and their sera gives a more firm 
support for the classification seropositive or seronegative. Our re-
sults are not affected, however, by a lower cut off value for seroposi-
tive/seronegative . 
The most striking differences between RF-/APF+ and RF-/APF- groups are 
seen in the development of radiological abnormalities after 10 and 15 
years of disease. Their (RF-/APF+) Larsen score is indistinguishable 
from that of RF-positive patients and after 10 and 15 years of the dis-
ease their score is significantly different from that of the RF-/APF-
group. 
The study of medication used by the patients leads to different obser-
vations. All patients were treated equally with hydroxychloroquine, 
aurothiolgucose and D-penicillamine. However, patients who were RF-po-
sitive were treated more often with cytotoxic drugs than the RF-negati-
ve groups. Two interpretations are possible. These differences could be 
introduced by physicians attending the patients; they could be biased 
by the presence of RF, into prescribing more toxic drugs. On the other 
hand, these drugs could have been needed by the patients in view of 
more complaints. Both suggestions seem likely, the former because RF is 
known to be a sign of poor prognosis and the latter because the higher 
ARA functional class and number of EAM are signs of more severe dis-
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ease. The high Larsen score and the relatively low medication index of 
the RF-/APF+ group could lead to the speculation that these patients 
were treated inadequately because of the absence of RF. The use of cor­
ticosteroids in rheumatoid arthritis is in our clinic mostly restricted 
to acute interventions in periods of exacerbations of the disease. And 
when patients remain on steroids for a longer period, the dose never 
exceeds 10 mg daily. So the number of patients that used steroids gives 
another overall impression of the disease than the SAARD's do. 
ANA are reported to be correlated with severity of RA (7,18). Linn et 
al (7) came to the conclusion that ANA+/RF- patients have a progression 
of their disease similar to that of RF positive patients. But their re­
port does not describe the values for the RF assays that are regarded 
as negative. So their definition of RF negative RA remains question­
able. From their data can be seen RF and ANA were strongly correlated, 
as was the case in our 132 patients. Our data analysed in the way Linn 
et al did, do not show the same phenomenon: ANA does not influence dis­
ease outcome in RF negative RA. Our data show that ANA and APF are not 
the same. Because ANA and APF show no relation in our total patient po­
pulation and also not in the RF negative patients, we conclude that APF 
is an antibody with distinct specificity and its own correlations with 
disease. The specificity of APF for RA makes it superior to ANA when 
evaluating RA patients. A study of a large group of seronegative RA pa­
tients divided in four groups (APF and ΑΝΑ-positive and negative) could 
definitely support our findings. In contrast with a lack of relation of 
APF and ANA, the latter was strongly related with RF; an observation 
also reported, although not mentioned by Linn et al (7). Details of 
this relation have been reported on by Hannestad et al (8) and by Ait-
cheson et al (19). The groups of Hannestad and Aitcheson found a subpo­
pulation of cross-reactive RF to be responsible for ANA activity. The 
relation between ANA and severity of disease can therefore be partially 
be ascribed to cross-reacting RF. The number of patients in our study, 
especially the number of RF negative patients does not allow us to di­
vide the patients in eight groups with respect to RF, APF and ANA. This 
would be the best way in separating effects, if any, of ANA from that 
of APF. The specificities of ANA were not analysed, so no conclusions 
can be drawn for ANA specificity and APF relations. The relation be­
tween APF and RF was only just statistically significant. No reliable 
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reports on the relation between these two antibody specificities have 
been published. 
The conclusion remains that APF is correlated with severity of disease. 
This phenomenon is most clearly seen in RF-negative patients and, al-
though less clearly, also observed in RF-positive patients. APF positi-
ve patients with RF negative RA behave in many respects like seroposi-
tive patients. 
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CHAPTER 6 
ANTIPERINUCLEAR FACTOR, A RHEUMATOID ARTHRITIS SPECIFIC AUTO-ANTIBODY: 
ITS RELATIONS TO EPSTEIN-BARR VIRUS 
A.A.A. Westgeest, A.M. van Loon, J.T.M. van der Logt, L.B.A· van de 
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SUMMARY 
We studied the prevalence of Antiperinuclear Factor (APF), a Rheumatoid 
Arthritis (RA) specific antibody, in different groups of patients. Sera 
from 123 RA patients and 28 patients with recent Epstein-Barr virus 
(EBV) infection showed APF in 63% and 51% of the patients respective-
ly. These frequencies were significantly increased (P<0.001) when com-
pared with those observed in 123 healthy blood donors (12%) and in 58 
patients with herpes virus infections other than EBV (18%). Relations 
with other EBV elicited antibodies in RA and the relevance of EBV in RA 
are discussed. Our data indicate that EBV might be the immunogen for 
APF, an antibody, until now considered to be an auto-antibody. 
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INTRODUCTION 
Antiperinuclear factor (APF) is an antibody reacting with cytoplasmic 
granules in human buccal mucosa cells. The precise antigenic specifici-
ty has never been elucidated (1). The strong relation of this antibody 
with rheumatoid arthritis (RA) (2) has never been refuted (3,4). In 
analogy with rheumatoid factor, we recently described a relation of the 
APF and disease severity in RA patients (5). 
Another series of antibodies found in sera of RA patients are antibo-
dies reacting with Epstein-Barr virus (related) antigens. After the 
initial report of the group of Tan (6) numerous papers have been publi-
shed about antibodies to Rheumatoid Arthritis Associated Nuclear Anti-
gen (RANA) and Epstein-Barr virus Nuclear Antigens (EBNA) in sera of RA 
patients (7,8,9,10). Structures and relations of these antigens have 
partly been elucidated (11,12,13,14,15) and functions of these viral 
encoded proteins have been studied (for a review, 15). Discrepancies in 
frequencies of anti-RANA and anti-EBNA in different groups of patients 
and controls have been reported and range from 6% to 56% (8,16,17,18). 
So, despite increased titres of anti-RANVanti-EBNA in RA patients, 
this antibody has no specificity for RA. 
We studied the prevalence of these RA related antibodies, APF and anti-
EBNA-1, in different groups of patients. Our investigations lead to a 
changing concept of antiperinuclear factor: "The immunogen could be of 
viral origin". 
MATERIALS AND METHODS 
A. Five different groups of sera were investigated. 
1. Hundred and thirty-two patients fulfilling revised criteria for 
definite or classical RA (19) with a disease duration of at least 
three years who have been described in more detail elsewhere (5). 
2. Fourty-one patients with systemic lupus erythematosus (SLE), all 
meeting the ARA criteria (20) (25 of these sera were a generous 
gift of Dr A.J.G. Swaak, Amsterdam). 
3. Hundred and twenty-four healthy blood donor volunteers were test-
ed as normal controls. 
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4. 58 patients with clinical signs and symptoms of EBV infections. 
Diagnosis was confirmed by detection of IgM antibody to the viral 
capsid antigen (VCA) (see below). 
5. Twenty-eight patients with symptoms suggestive of infections with 
herpes virus infections, other than EBV. Eight had cytomegalovi-
rus/ 12 had varicella zoster virus and eight had herpes simplex 
virus type I infection. These diagnoses were confirmed by demon-
stration of virus specific IgM antibodies (27). 
Age and sex distributions of these groups of patients and controls 
are given in table 1. The five patients groups are referred to as 
RA, SLE, BLO, EBP and HER respectively. 
B. The following assays were used to test sera for the presence of an-
tibodies. 
1. Antiperinuclear Factor assay. 
The technique used, was in general as described previously (5).In 
short, the procedure was as follows. Sera were diluted 1:10 in 
phosphate buffered saline (PBS; 0.01M phosphate buffer pH 7.2, 
0.14M NaCl) and incubated with cytocentrifuge preparations of hu-
man buccal mucosa cells for 90 minutes at room temperature. After 
three washings with PBS of 10 minutes each, antibodies were de-
Table 1. Age and sex ratios of patients and controls. 
patients 
group 
RA 
SLE 
BLO 
EBP 
HER 
number of 
sera 
132 
41 
124 
58 
28 
mean(SD) 
58.3(10.9) 
40.1(13.3) 
36.1(9.8) 
19.0(15.6) 
24.4(15.9) 
age (years) 
minimum 
28.4 
17.5 
18.3 
1.4 
1.3 
maximum 
83.0 
67.3 
59.2 
70.9 
54.1 
female 
n(%) 
96(73) 
37(90) 
62(50) 
27(47) 
10(36) 
RA = rheumatoid arthritis; SLE = systemic lupus erythematosus; BLO = 
blood bank donors; EBP = patients with Epstein-Barr virus infections; 
HER = patients with herpes virus infections, except EBV. 
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tected with a fluorescein isothiocyanate conjugated (FITC) sheep 
anti-human immunoglobulin antiserum. After the conjugate incuba­
tion of 30 minutes and three washings of 10 minutes, preparations 
were mounted with glycerol (50%) (v/v) in PBS containing 0.5 цд 
ethidium bromide and read with a fluorescence microscope. Sera 
were scored from negative, weakly positive, positive to strong 
positive. 
2. Anti-EBNA-1 test. 
RAJI cells (a non-producer EBNA-1 positive B-cell line) were used 
as a source of nuclear material in an inmunoblot test (IBT). 
Nuclei were prepared as described (22). In short, cells were har­
vested in logarithmic growth phase and lysed in hypertonic buffer 
containing 0.5 mM phenylmethyl sulfonyl fluoride (PMSF, a prote­
ase inhibitor) and 10% Triton X-100. After pelleting and washing, 
the nuclei were disrupted with hypertonic buffer and treated with 
DNA'se and RNA'se in the presence of magnesium and calcium ions. 
The nuclear material was prepared for sodiumdodecyl sulfate gel 
electrophoresis as described (23) and separated on 13% Polyacry­
lamide gels. After blotting to nitrocellulose (24), blots were 
incubated with sera diluted 1:30 (25) in a blot incubator (26). 
After detection of IgG antibodies with a horse-radish peroxidase 
conjugated antiserum and 4-chloro-1-naphtol as substrate, sera 
were scored for the presence of a band with a molecular weight of 
70 kilo Dalton (10,11). A semiquantitative score was used, 
ranging from negative (-), weakly positive (+), positive (++) to 
strongly positive (+++). 
3. Epstein-Barr virus Capsid antigen test. 
Anti-EBV-VCA antibodies was tested for by means of an indirect 
immunofluorescence test on P3HR-1, cells (21). Sera were diluted 
in two-fold dilutions starting at 1:16. A titre of 1:32 or more 
was regarded as positive. 
4. Antinuclear antibody assay. 
Sera were tested for antinuclear antibody (ANA) with 4 μπι cryo­
stat sections of rat liver as substrate . Sera were tested in a 
1:10 dilution with the same FITC conjugated antiserum as used in 
the APF assay. Sera were scored as negative or positive. 
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BLO, EBV and HER sera were tested under coded conditions for APF. 
Not all sera were tested in all antibody assays. Selections were 
made without any preference, unless otherwise stated. 
C. Statistics. 
Data were analysed with the SAS package (SAS institute Ine, Cary 
NC). Chi square statistics with Yates continuity correction were 
used for 2 x 2 tables. Fisher's exact test was used when expected 
cell frequencies were less than five. Differences in mean ages were 
tested by means of a t-test for two independent samples. Wilcoxon 
Rank Sum test for two independent samples was performed for the com­
parison of antibody titres. Ρ values less than 0.05 were regarded as 
significant. When appropriate 95% confidence intervals were calcu­
lated (28). Kendall's Tau was calculated as a measure of correla­
tion. 
RESULTS 
Due to the different origin of the four groups of patients and the con­
trols, mean ages of the five covers a wide range. These differences in 
mean age of the various groups have consequences for the anti-EBNA-1 
antibodies (see below). For sex ratio's, RA and SLE groups differed 
both significantly from the other three groups; BLO, EBP and HER were 
not significantly different. RA and SLE groups had a larger proportion 
of female patients. 
Antiperinuclear factor. The results of 368 sera tested for APF are sum­
marized in table 2. RA and EBP groups are nearly similar in their fre­
quency of APF positive patients as is seen from 95% confidence inter­
vals and Ρ values. Both differ significantly from healthy controls 
(BLO). Age differences between different groups could not be corrected 
for, but when from the RA group only those patients were analysed with 
an age of less than 60 years, the percentage of APF positive patients 
remains exactly the same (63%). In the BLO group we found no differen­
ces in APF positivity between males and females. Although the APF fre­
quency is slightly increased in the HER group, both SLE and HER groups 
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are not different from the BLO group. 
Anti-EBHA-1 antibodies. Semiquantitative scores of anti-EBNA-1 antibo­
dies assayed with an IBT are given in table 3. Only the EBP group shows 
an increased frequency of anti-EBNA-1 negative patients: 85 compared to 
44 (HER), 34 (RA), 34 (BLO) to 29 (SLE) percent . Although the percen­
tage of anti-EBNA-1 negative patients in the HER group is slightly in 
Table 2» Sera tested for antiperinuclear factor. 
patients* number positive 95% conf. Chi square Ρ value with 
group tested η % interval of with respect respect to 
positives to 
BLO EBP BLO EBP 
RA 
SLE 
BLO 
EBP 
HER 
123 
39 
123 
55 
28 
78 
3 
15 
28 
5 
63 
8 
12 
51 
18 
54 - 72 
0 - 1 7 
6 - 1 8 
38 - 64 
4 - 3 2 
6 8 . 4 6 
** 
29.01 
** 
1.28 
17.38 
29.01 
7 .14 
< 0 . 0 0 1 
= 0 . 3 3 
< 0 . 0 0 1 
= 0 . 3 0 
= 0 . 1 6 
<0.001 
<0.001 
= 0 . 0 0 8 
* For abbreviations see table 1 
** Fisher's exact test was used 
Table 3. Anti-EBNA-1 titres in five groups of sera. 
p a t i e n t s * 
groups 
RA 
SLE 
BLO 
EBP 
HER 
number 
t e s t e d 
68 
14 
84 
58 
27 
score in EBNA-1-IBT(percentages)* 
- + ++ +++ 
34 
29 
33 
85 
44 
29 
36 
31 
7 
30 
13 
36 
31 
2 
22 
24 
0 
5 
7 
4 
* for abbreviations see table 1. 
** for scores in anti-EBNA-1 immunoblot test, see section material and 
methods. 
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creased (compared with BLO) the difference is not statistically signi­
ficant (Fisher's exact test: P=0.54) and is attributable to the diffe­
rences in mean age of the HER and BLO group. When only patients of at 
least 20 years of age are analyzed, the frequency of anti-EBNA-1 nega­
tive sera is as follows: RA 34%; SLE 28%; BLO 33%; EBP 80% and HER 25%, 
thus showing a "normal" frequency of anti-EBNA-1 in the HER group. 
Scores of anti-EBNA-1 are not different in the BLO and RA groups when 
tested with the Wilcoxon Rank Sum test (z « 1.11, Ρ = 0.27). Sixty-four 
RA serum samples were tested two times by independent observers with 
two different batches of RAJI antigen and scored independently, the se­
cond time without knowledge of the first test results. Correlations 
were good: only two sera scored negative in the first and weakly posi­
tive on the second test. All other sera showed the same score in first 
and second test (Kendall's Tau = 0.974). 
Antinuclear antibody. 131 RA, 124 BLO and 57 EBP sera were tested for 
ANA activity. The patients with RA presented a frequency of 54% posi­
tive sera. BLO and EBP group were equal in their percentage of ANA po­
sitive sera: 5 and 7 percent respectively. 
Anti-EBV-VCA antibodies. Of the BLO group 14 of the 15 APF positive 
sera (one sample was out) and 15 randomly chosen APF negative sera were 
tested for IgG antibodies to EBV-VGA. Serum titres ranged from 1:32 up 
to 1:8000 in both groups, median titres were 1:1024 and 1:2048; geome­
tric mean of titres 1:1448 and 1:1482 for APF negative and APF positive 
BLO respectively. 
Substrate donors. Previous to all our experiments ten healthy persons 
(laboratory workers, age 23 to 36 years, three female) were screened 
for the presence of the APF antigen. This screening was performed by 
means of 4 different positive sera, including a national reference se­
rum for APF (29). Eight of the 10 donors showed the presence of the an-
tigen in three different buccal mucosal cell preparations, obtained 
with at least three week intervals. Two donors were consistently nega­
tive when tested with APF positive sera. With none of the sera any 
fluorescence indicating APF antigen was seen with their cell prepara-
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tions. Eight of the ten donors showed serologic signs of a previous EBV 
infection (IgG anti-VCA and anti-EBNA-1). Only one had a positive his-
tory of infectious mononucleosis. Six APF antigen positive and two APF 
antigen negative donors were positive for anti-EBV-VCA and anti-
EBNA-1. However, two APF antigen positive donors had no anti-EBNA-1 and 
anti-EBV-VCA in their serum. From the latter four persons, a second se-
rum sample was tested with exactly the same results. 
DISCUSSION 
Our observations indicate a strong relationship between a recent infec-
tion with Epstein-Barr virus and the appearance of antiperinuclear fac-
tor. RA patients and patients with recent infection with EBV did show 
high frequencies of APF; patients with other virus infections and 
another generalized auto-immune disease as well as healthy blood donors 
did not. 
Increased frequencies of APF antibodies found in sera of patients with 
RA again raises the question of what is first: RA or the virus. Do per-
sons with a certain genetic background (and probably other factors) get 
RA due to an infection with EBV or do patients with RA have problems in 
handling of EBV and therefore present features of recurrent infections 
with the virus. With our data in mind, none of these two hypotheses is 
more likely to be true. Our results only point to the EBV as an immuno-
gen for APF-antibody, thus far thought of as an auto-antibody. A third 
possibility (and with regard to EBV not very unlikely) is that the vi-
rus is not acting as an immunogen (antigen) but as a more or less spe-
cific polyclonal B-cell activator. In our EBV patients, however, the 
increased frequency of APF is not a consequence of increased immunoglo-
bulin synthesis; if that was the reason for the increased APF frequen-
cy, the ANA frequency would probably also be increased. From the lack 
of ANA in the EBP group we concluded that APF production is a conse-
quence of specific antigenic stimulation of the virus and not an aspe-
ciflc B-cell activation. Our results of the anti-EBNA-1 in RA and BLO 
groups seem to be in contrast with a reported increase in frequency or 
titre in RA patients of this antibody. But the semiquantitative score 
we used is probably the reason for the lack of different "titres" in 
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the two groups mentioned, when tested by Chi-square analysis, the fre-
quency of strongly positive sera (+++) is increased in the RA group. 
In contrast with antibodies to intermediate filaments, APF antibodies 
are not produced after infection with other herpes viruses (30). The 
slightly (but not significantly) increased frequencies of APF that we 
found in the HER group, compared with the SLE and BLO groups is proba-
bly a consequence of the epidemiology of EBV. The mean age of the HER 
group is comparable to the mean age of the EBP group, so although we 
did not test the HER group for recent EBV infections by means of IgM 
anti VGA, there could be a number of HER patients with recent EBV in-
fections. The relative large proportion of anti-EBNA-1 negative HER pa-
tients supports this idea. 
The large proportion of blood donors, presenting with signs of a pre-
vious infection with EBV (anti-EBNA-1 positive) and the low frequency 
of APF in this group indicate that after the infection with EBV, the 
APF disappears. It would be of interest to study sera of patients with 
primary EBV infections over a longer period of time for APF, to get in-
sight in the appearance and disappearance of APF related to the other 
EBV antibodies. 
Our finding of about half the patients with EBV presenting a positive 
APF test, is probably a matter of chronology. The number of days be-
tween infection and serum sampling is not known in the majority of pa-
tients. A rapid rise and fall of APF antibody during the course of the 
disease is a possible explanation for the lack of a 100% correlation of 
EBV infection and APF. There is one report (31) in which APF and EBV 
relations were sought for. No increased frequency of APF was found in 
patients with a positive Paul-Bunell test. These sera were selected in 
another test than ours (IgM anti-VCA) and our APF assay system has 
higher sensitivity due to the use of more diluted serum (data not 
shown). 
The prevalence of APF is also specific for RA and not seen in another 
generalized auto-immune disease with overproduction of auto-antibo-
dies. While the pecentage of EBNA-1 positive SLE sera is the same as in 
the BLO and RA groups, thus indicating the same proportion of patients 
infected with EBV, there is no increased frequency of APF in SLE pa-
tients. This normal frequency of APF in SLE patients has also been re-
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ported by others (2,3,4). 
Our first idea that the presence of APF in normal healthy blood donors 
represents reactivation of an EBV infection seems to be wrong. The 14 
APF positive blood donors had the same titre of IgG anti-EBV-VCA as 15 
APF negative blood donors. So the low percentage of APF positive blood 
donors remains an unexplained phenomenon. 
This frequency of positive sera in a group of healthy individuals re-
presents probably a "background" production of auto-antibodies. The 
difference observed between RA and BLO groups is not caused by diffe-
rences in age distribution or sex ratio's in the two groups, as is seen 
when only the relative younger RA patients are analysed. Moreover, 
Nienhuis in his original studies found no increased frequency of APF in 
a group of 195 elderly people (age 65 years) and no differences of APF 
distribution among the two sexes. 
Human buccal mucosa cells are known to contain and shed EBV (32). The 
APF antigen could be of viral origin or a viral modified host protein. 
On the condition that all donors positive for the antigen had had a 
previous infection with EBV the origin of the antigen could with some 
certainty be ascribed to the virus. But in our material two antigen po-
sitive donors were negative for antibodies to EBV (anti-VCA and anti-
EBNA-1). In their original report, Alspaugh et al also tested Rheuma-
toid Arthritis Precipitin (RAP) positive sera on human buccal mucosa 
cells (6), but were not able to detect fluorescent cytoplasmic gra-
nules. Although there are differences in their APF testing and our 
method, this means that the APF antigen is not similar to RAP or 
EBNA-1. 
So the question remains open and the host origin of the antigen seems 
more likely. The antibody is probably viral elicited and cross reacts 
with human proteins. Whether this crossreactivity is caused by structu-
rally identical epitopes in the virus and the buccal mucosa cells or by 
the fact that one antibody can react with two structurally different 
antigens is not elucidated by our experiments. Inhibition experiments 
and characterization of the antigen is subject of recent work in our 
laboratory. Untili these questions are answered, the localization of 
the antigen in buccal mucosa cells is then considered as a coincidence. 
Our data, so far, do not provide evidence for an etiologic role of EBV 
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in RA, but only give some insight in the origin of a very RA specific 
"auto-antibody", in our opinion antiperinuclear factor is present in 
sera of RA patients as a consequence of recurrent exposure of these pa-
tients to Epstein-Barr virus. The virus elicited antibody is probably 
cross reacting with epitopes of human cell constituents. It is there-
fore questionable to speak of antiperinuclear factor as an auto-antibo-
dy. 
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INTRODUCTION 
The diagnosis rheumatoid arthritis (RA) is first of all based on clini-
cal manifestations. In patients with full blown disease in which all 
characteristics are present, diagnosis is most of the time no problem. 
But in cases of early disease or disease of a very mild character esta-
blishing a diagnosis poses the clinician sometimes for a difficult pro-
blem. No erosions can be observed on radiographs and biopsies are not 
very helpful. Only few laboratory tests are of any value, and of those, 
rheumatoid factor (RF) determination contributes possibly the most to 
the diagnosis. A positive test has a predictive value (1) and is relat-
ed to disease with a more severe outcome (2). The origin and the patho-
physiological role of RF however, can only be speculated on. RFs are 
nowadays presented m many reports as being crossreactive with all dif-
ferent kinds of antigens (nuclear, viral, bacterial) (3,4,5,6). It is 
not known whether this crossreactivity is on the level of antibody (one 
idiotype reacting with different antigenic determinants) or on the le-
vel of antigen (different antigenic substrates presenting the same epi-
tope). Another, but less widely used antibody is the so-called antipe-
nnuclear factor (APF). This antibody has great specificity for RA (7) 
and is, like RF related with disease severity (8). A third antibody 
specificity is the antinuclear antibody (ANA). In fact this is a group 
of antibodies of which only a limited number of the antigens are cha-
racterized. Interest in this antibody and its relations with RA was 
raised in the early sixties when the concepts about systemic lupus ery-
thematosus (SLE) and RA were changing. Studies showed that "ANA" in its 
overall way was not differentiating between SLE and RA (9,10). However, 
from that time on ANA testing was used in management and research of 
RA. 
Review from the literature of RA and auto-antibodies gave us the im-
pression that the value of ANA was over- and the value of APF was un-
derestimated. ANA are in no way specific for RA and crossreacting RFs 
have been shown to be responsible for at least part of ANA activity. In 
contrast, APF has always been reported to be RA specific and crossreac-
tions with RF have not yet been proven. 
In this paper we want to present a review of the recent literature on 
ANA and APF in RA, with special emphasis on crossreaction with RF. We 
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will discuss technical problems of assay systems, crossreactions with 
RF and clinical relevance of both antibodies. Some suggestions are pre­
sented about future research on ANA and APF. 
Technical details of ANA determinations 
The most frequently used assay to test for ANA is an indirect immuno­
fluorescence test (IFT), employing tissue sections or cell-line sub­
strates of either animal or human origin. Mostly, an antiserum directed 
against all (or at least IgG, IgM, IgA) immunoglobulin classes is used 
as a second step. In general it can be stated that no real differences 
exists between different substrates. But there are exceptions to this 
rule. Of course one particular antigen is present more abundant in for 
example HEp-2 cells than in rat liver tissue sections and so a specific 
serum may be positive for ANA on the former and negative when tested on 
the latter substrate. Although one report states the opposite (11), it 
is our own experience and that of others (RJT Smeenk, personal communi­
cation) (12,13) that there is only a slight difference in sensitivity 
( slightly higher titres are reached) between rat liver sections and 
HEp-2 cells in advantage of the latter. In gross, both substrates reach 
the same sensitivity and specificity when sera are scored positive and 
negative. In general IFTs can be employed to screen for ANA and to es­
tablish titres of antibodies. Dilutions of sera are chosen in such a 
way that a certain preset percentage of positives in a group of normal 
control sera is not overridden. Obviously this matter is different when 
for example anticentromere antibodies (АСА) or some other peculiar an­
tibody specificities are studied. These antibody specificities, for 
example АСА or antispindle figure antibodies are not easily detected 
with rat liver sections, but require specific substrates (14). Since 
these antibodies are almost absent in sera of RA patients (15,16) and 
more sophisticated assays like immuno diffusion or immunoblot technique 
are available nowadays, these antibodies do not present any problem in 
ANA testing in RA patients. Of the wide spectrum of known ANA, only 
SS-Α (La) and SS-B(Ro) antibodies are frequently observed in RA (15, 
16). These antigens and their antibodies have been well characterized 
(17,18) and have no relations with RF. 
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Finally, one substrate for ANA-IFT deserves special attention. In a se-
ries of papers (for a list of references see 19) Wiik presented eviden-
ce for an RA specific ANA when using human granulocytes as antigen 
source. Sera of RA patients showed a bright fluorescence on granulocyte 
nuclei and were negative on lymphocytes on rat liver or kidney. Pa-
tients with other rheumatic diseases and normal controls did not show 
the phenomenon. This antibody is easy to distinghuish from the Wege-
ner's disease specific anticytoplasmic antobody, since the latter shows 
cytoplasmic instead of the nuclear fluorescence present in some RA se-
ra. in their papers, Wiik and his group did not present any details of 
the antigen. But since sensitive techniques like immunoblotting are 
available it is worthwhile testing sera with human granulocytes as an-
tigen and thus decipher the granulocyte specific antigen. In our hands, 
immunoblotting with RA sera, with Hela cells as antigen has thus far 
not shown any specific antigen to be responsible for ANA activity in RA 
sera. 
Crossreactions of rheumatoid factors and antinuclear antibodies 
Some elaborate studies, of which the first appeared in 1976 (20) by 
Hannestad and coworkers, have given some insight in crossreacting RF. 
They showed that RF of IgG class in a serum of an RA patient was re-
sponsible for 100% of the ANA activity in that serum (21). The charac-
terized antigen was contained in the chromatin subunit, called nucleo-
some. These nucleosomes contain repeating DNA-histone units (22).In a 
more extensive study by the group of Aitcheson and Tan (23) 27 RA pa-
tients were tested for ANA. Sixty percent of the sera were positive on 
a "routine IFT"; almost none contained antibodies of known ANA specifi-
city, except 14 sera containing anti-histone antibodies. After isola-
ting highly pure RF by means of precipitation, gel filtration under 
acid conditions and affinity chromatography they showed that these RFs 
contained ANA activity with a histone-dependent antigen. In another 
more recent paper (24), affinity purified RFs showed to be crossreac-
tlve with a DNA/histone antigenic determinant. In an IBT, these RF 
showed strong reaction with a 94kD protein and a weaker reaction with 
a 48 and a 200 kD nuclear protein. But the RF preparations were prepar-
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ed by affinity chromatography only and were shown by the authors to 
contain IgG. Cross reactions have now been clarified partially on gene­
tic level. Recently, it was shown that germline genes encoding variable 
regions of RF, show homology with sequences obtained for anti-dsDNA 
antibodies. This is shown for heavy (25) as well as for light chain 
genes (personal communication, BD Stollar and H Dersimonian). 
Concluding from these studies, one can say that major part of the ANA 
activity in sera of RA patients could be due to a minor part of the RF 
showing crossreactivity with nuclear antigens. Aside from these ANA-RF 
antibodies, these sera could contain other, non-crossreactive ANA spe­
cificities (figure 1). 
Clinical studies on ANA and rheumatoid arthritis 
Table 1 resumes the results of recent reports on ANA and RA. Most of 
these studies were not specially designed to study ANA and RF rela­
tions. This makes evaluation even more worthwhile because patients were 
Table 1. Studies performed in RA patients and patients with other rheu­
matic diseases, which mentioned RF and ANA and relation between these 
two antibody assays. 
author 
Linn 
Steven**** 
Walton**** 
Papiha 
Panayi 
Westgeest 
ref/year 
26/1978 
27/1984 
28/1985 
29/1986 
30/1987 
8/1987 
number of 
pat ients studied 
401 
470*** 
105 
225 
94 
132 
χ 2 * 
18.75 
30.45 
5.82 
** 
19.19 
13.45 
Ρ 
<0.0001 
<0.0001 
=0.016 
=0.13 
<0.0001 
<0.001 
* Chi square analysis with Yates correction for RF positive or ne­
gative versus ANA positive or negative. 
** Fisher's exact test was used. 
*** 470 patients included 156 patients with RA and 314 patients with-
other rheumatic diseases. 
**** The studies only allow analysis of high titre versus low titre 
sera. 
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Figure 1. Patients with rheumatoid arthritis and two auto-antibody specificities; their relations with 
the antigens. Drawn lines represent known relations, broken lines depicts possible relations and ques­
tion marks depict unknown antigens. 
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enclosed without any prejudice of ANA. In all but one paper significant 
relations exist between ANA and RF. The report by Papiha (29) describes 
a study of genetic markers in 225 RA patients of which 209 (93%) were 
RF positive. Only one of the 45 ANA positive patients was negative for 
RF. But because the fraction of RF negative patients is so small (7%), 
it is not surprising that statistical testing does not yield a signifi­
cant relation between ANA and RF. If the only RF negative ANA positive 
patient also had been RF positive or ANA negative, a Ρ value of less 
than 0.05 would have been reached. The studies by Steven et al (27) and 
by Walton et al (28) do not allow analysis of RF positive and RF nega­
tive RA patients, since these papers give only details of high versus 
low titre RA sera. In addition, the study of Steven (27) only provides 
numbers of all 470 subjects tested, summarizing the tests of sera of 
patients with osteoarthritis, RA,connective tissue diseases and a group 
of miscellaneous rheumatic diagnoses. In RA patients, ANA is not relat­
ed to disease severity but their way of measuring disease severity is 
very indirect (drugs used by the patients and surgical intervention as 
mentioned in the medical records). The case control study of Linn et al 
(26) does find a correlation between ANA and disease severity, as was 
measured by radiographic changes. Although not mentioned by the 
authors, the 401 original patients included in the study show a highly 
significant relation for ANA and RF. The recent case control study of 
Panayi et al (30) also discloses a significant relation between RF and 
ANA. Disease severity is not mentioned in relation to ANA. In our own 
group of patients (8) we found a significant relation between ANA and 
RF but were not able to show a relation of ANA with disease severity 
(measured by radiographic scores). 
Conclusions on ANA and RF in RA 
There seems to be a tendency to think of ANA in RA as being correlated 
with a worse disease outcome. But since RFs have been shown to be reac­
tive with nuclear antigens, data on ANA and disease severity have to be 
interpreted with great care. One has to be sure that an effect of ANA 
on its own is studied. The cut-off value of seropositive and seronega­
tive has to be presented in the study (this point was neglected in the 
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paper of Linn et al (26)). Even then, non-agglutinating RF of IgG class 
could be responsible for ANA activity, and thus indirectly relate ANA 
to disease severity. Knowing the results of the Scandinavian studies of 
granulocyte specific ANA in RA, future research should be directed 
towards these unspecified granulocyte antigens. Care should be taken in 
studying ANA in RA, because of the known crossreactivity in sera of RA 
patients. 
Technical considerations of APF assay 
There is one major problem when comparing different studies on APF and 
that is the dilution of the serum used in the IFT. Although different 
substrates have been tested (31,32) no reliable alternative has been 
found. So all studies used human buccal mucosa cells. As said above, 
the major point of difference is in the serum dilution used, running 
from undiluted to 1:10, and some studies titrate the serum to an end 
point in the IFT. Although one study does not mention the serum dilu-
tion used one can assume that they used undiluted serum: "...cell pre-
parations were flooded with serum...." (31). The percentage of posi-
tive sera in groups of RA patients in different studies is given in 
table 2. Not all studies available were included in this table because 
a large number of papers from the group of Youinou, two papers from the 
group of Holborow and two papers of the group of Feltkamp could, proba-
bly be presenting data on the same group of RA patients. Only the two 
studies by Holborow and coworkers present different percentages in both 
papers 81% (up to 92% when weak positives were included) in the first 
(34) and 74% in the second paper (38). They used 1:5 diluted serum in 
both studies. Studies published by other groups, presented grossly con-
stant frequencies throughout all their reports. The percentage of posi-
tive sera in groups of RA patients is clearly related to the dilution 
used in the IFT. It is our own experience (table 3) that when we tested 
the same group of sera of RA patients undiluted as well as diluted 
1:10, the frequency of positive sera increases considerably: from 24% 
to 63% (see table 3 ) . Almost no sera (3 out of 30) sera changed from 
positive to negative or weak positive when tested in a 1:5 dilution. 
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Table 2. Percentages of positive sera for APF in RA patients, summariz-
ed from the literature. 
author ref/year sera tested 
(n) 
positive sera dilution 
(%) tested 
Nienhuis 
Marmont 
Sondag-Tschroots 
Johnson 
Youinou 
Cassani 
Janssens 
7/1964 
31/1965 
33/1979 
34/1981 
35/1983 
36/1983 
37/1987 
105 
100 
103 
102 
178 
90 
127 
49 
52 
78 
81(92)* 
68 
82 
86 
undiluted 
undiluted 
5 
5 
5 
5 
5*. 
* Percentage positives increases from 81 to 92 when weakly positives 
are included. 
** Personal communication. 
Table 3. 123 sera from RA patients tested for APF, undiluted and in a 
1: 10 dilution. 
sera tested undiluted 
sera tested 
1:10 diluted 
( + ) 
+ 
++ 
-
32 
7 
25 
8 
( + ) 
3 
0 
13 
5 
+ 
2 
1 
5 
14 
24% 
++ 
0 
0 
3 
5 
41% 
63% 
70% 
test results are expressed as followes: - = negative, (+) = weak posi-
tive, + = positive, ++ = strongly positive 
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Table 4. 58 Sera sent in for routine determination of APF; assay re-
sults in two APF assays and clinical diagnosis. 
APF assay: UNDILUTED DILUTED 1:10 
results : pos neg pos neg 
DIAGNOSIS 
RA 1 17 17 1 
NON RA 0 40 U 29 
1 57 28 30 
In another experiment we tested 58 consecutive sera, send to our labo-
ratory for routine determination of APF, in both undiluted and diluted 
form: 1 was positive in the former, and together with this one, another 
27 scored positive in the diluted test (table 4). When medical records 
of these patients were examined , 61% of the patients positive in the 
diluted test had a diagnosis of RA. The other way around, of the total 
of 18 patients with RA of this group of 58 only 1 (6%) was positive 
when tested undiluted, whereas this increased to 17 (94%) when their 
sera were tested in a 1:10 dilution. When a number of 123 blood donors 
were tested, the number of positive sera increased from 6% to 12% when 
sera were diluted before assayed. This phenomenon of increased numbers 
of positives in controls is to a lesser extent also seen in the refe-
rences indicated in table 1. 
We did experiments which gave us some indication that this lesser sen-
sitivity of the undiluted test is due to a pH effect , caused by the 
test serum, a phenomenon known to influence antigen antibody interac-
tions (39). The decreased sensitivity did not seem to be caused by 
background staining when undiluted sera were tested. 
Some studies described increased frequencies of APF in thyroiditis 
(33,40), Sjogren's syndrome (33,41) and psoriasis (35) Thyroiditis 
(42) as well as Sjögren are known to be related with RA. Overall, APF 
is a specific antibody for RA in comparison with well defined groups of 
patients (SLE, osteoarthritis) or healthy donors. 
The major drawback of the APF-IFT is the nature of the substrate. Ob-
taining human buccal mucosa cells is easy, but only a small percentage 
of the donors has antigen present of such a quality and in such a quan-
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tity that they are suitable to be used. Sondag-Tschroots (33) states 
that only 10% of the donors have the antigen in a satisfactory amount. 
Youinou tested 135 (!) substrate donors (35) and found the antigen in 
31 cases. After extensive search in 10 donors in our lab, eight showed 
to be presenting the antigen, two were negative with a number of posi-
tive sera on every occasion tested (at least three times). Because of 
weak antigen presentation or repeated contamination with bacteria, only 
two of the eight were suitable for regular APF testing. Nienhuis, in 
his original publication (7) reported all 20 donors tested, te be posi-
tive for the antigen. We think the proportion of antigen positive do-
nors is high ( 80%). But due to repeated bacterial contamination or the 
quality (small granules) of the antigen, the frequency of donors suit-
able for substrate use, is rather low (10%-20%). 
Crossreactions of RF and APF 
In analogy with ANA, it is of great interest to know whether APF acti-
vity in sera of RA patients is a consequence of crossreactive RF or 
not. Youinou and coworkers (43) presented one study covering this 
point. From two sets of experiments they concluded that part of the APF 
activity was due to RF in the sera tested. Firstly, they purified RF by 
means of affinity chromatography and showed that this preparation had 
APF activity. Secondly, APF titres were decreased after incubation of 
the sera with aggregated IgG. With regard to the purification of RF, it 
is clear from their study that their methods are in no way comparable 
to be methods used by Aitcheson (23). Because of possible contamination 
with IgG, their (Youinou) results should be interpreted with reserva-
tions. The inhibition experiments they performed do, in our opinion, 
not allow the conclusions they draw. When a serum, containing APF and 
RF, is tested for APF, the RF present in the serum possibly amplifies 
the APF fluorescence, by binding to the (polyvalently presented) IgG-
APF antibodies. When RFs are removed from this serum, a drop in APF 
titre is then no argument for APF activity from RF in that serum. 
When clinical studies on APF, RF and RA are reviewed with special at-
tention to the relation between APF and RF these two antibodies show a 
correlation that does not seem to be as strong as was for ANA and RF 
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Table 5. Studies performed in RA patients, which mentioned RF and APF, 
and the relations between these two antibodies. 
author 
Nienhuis 
Marmont 
Sondag-Tschroots 
Johnson 
Youinou 
Cassani 
Westgeest 
ref/year 
44/1965 
31/1965 
33/1979 
34/1981 
35/1983 
36/1983 
8/1987 
number of 
patients 
studied 
248 
100 
103 
83 
178 
90 
132 
X2 
3.73 
14.18 
25.02 
0.29 
6.16 
12.86 
4.26 
Ρ value 
= 0.10 
<0.001 
<0.001 
= 0.70 
<0.02 
<0.001 
<0.05 
* Chi square analysis with Yates correction for RF positive or negative 
versus APF positive or negative sera. 
(table 5) . Three of the seven studies reach a Ρ value of less than 0.01 
and the overall picture is not as homogenous as for ANA/RF relations. 
Although tried by means of histocytochemical techniques (32,44) the an­
tigenic substrate has not been characterized. Electronmicroscopic stu­
dies indicate that the antigenic determinant is contained in the so 
called keratohyaline granules (personal communication W van Venrooy 
(45)). Biochemical characterization is now in progress in our depart­
ment. We recently performed experiments in which we showed that 50% of 
patients with recent Epstein-Barr virus (EBV) infection show APF in 
their serum. This was not due to specific В cell stimulation but seemed 
to be a specific antigen driven antibody response. Although not charac­
terized, we have the impression that the antigen is one of the EBV in­
duced proteins appearing on B-cell after EBV transformation/infection 
(submitted for publication). 
Clinical studies of APF and RA 
Opinions whether there is a relation of APF with disease severity, dif­
fer among the cited authors. In his early studies , Nienhuis (7)indi-
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cated that some relation could exist. Marmont (25) reported a relation 
of APF and the stage of disease (a scale from I to IV, a combined mea­
sure of clinical and laboratory values). Johnson (34) found no relation 
between C1q binding (a measure for soluble immune complexes) and APF. 
Youinou reported a correlation (r=0.51, Ρ 0.001) between the actual 
activity of the disease and the APF titre (46). All these studies had 
two major points of concern. Firstly, the discrimination of positive 
or negative APF relied on only one determination of this antibody. Some 
patients described in our study (8) showed a tendency to be positive 
during only a limited period of time, but were regarded APF positive. 
This is a similar phenomenon as shown by RF and an accepted method of 
grouping patients positive and negative for a given antibody. Disease 
activity gives just a very momentarily impression of the disease and 
when scored by means of C1q binding, measured in an indirect way. Gene­
rally accepted values like Ritchie index, total joint score, erythro­
cyte sedimentation rate or C-reactive protein levels are more objec­
tive, reliable and preferable measures of disease activity. But instead 
of disease activity, disease severity gives a better impression of the 
degree in which a patient is attacked by the disease. Measures of dis­
ease severity are for example radiographic scores or cumulative data on 
drugs. And above all, in the studies that showed a correlation between 
RF and APF, relations observed between APF and disease severity/activi­
ty can be partially attributed to RF and its relation with disease out­
come. Our own report (8) is in fact the only study that shows a rela­
tion between APF based on longitudinal antibody determinations, and 
disease severity. We showed that RF negative APF positive patients had 
a disease course similar to RF positive patients. 
Concluding remarks on APF and RA 
APF is an antibody characteristic of RA, directed against an unknown 
antigen. Cross reactive RF could be responsible for APF activity in 
some sera but that has to be confirmed by more extensive studies. The 
presence of the antibody is related to disease severity and this is im­
portant in cases of seronegative RA. In this way APF is a prognostic 
factor like RF and should be incorporated as such in management of RA 
patients. 
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CONCLUDING REMARKS 
Where to go from now on. The fact known from ANA in RA are: 1) Crossre-
acting RFs are in part responsible for ANA activity. 2) The antigen in-
volved in this crossreacting is an DNA-histone determinant. 3) Granulo-
cyte specific ANA have the best specificity for RA but the antigen has 
not yet been characterized. 
Considering these three points it seems at least interesting to focus 
more attention to granulocyte nuclei and to unravel the antigenic con-
stituents by means of modern biochemical and immunochemical techniques. 
This will probably not lead to more insight in the pathogenesis of RA 
but will tell us more about the nature of antibody responses in rheuma-
toid arthritis. Compared to ANA and RF, APF is an antibody with a much 
higher specificity for RA. The sensitivity is comparable to RF. Remarks 
about specificity and sensitivity of APF are up till now always made 
with reference to other well defined groups of patients or relative 
small groups of controls. In only one paper (36) a very crude estima-
tion is made about the "predictive value of a positive APF". An epide-
miologic survey from our department, attending this question, is sub-
mitted for publication. Determination of APF in the workup of patients 
with joint complaints and RA in the differential diagnosis is a useful 
addition to the widely used RF determination. In this setting, ANA de-
termination seems of less value. 
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SUMMARY AND CONCLUSIONS 
The studies described in this thesis, mainly deal with antibody assays: 
the immunoblot test (IBT) for antinuclear antibodies (ANA) and an assay 
for antipennuclear factor (APF). The former is a relatively new assay, 
introduced in serodiagnosis of the rheumatic diseases; the latter is a 
well known antibody assay for rheumatoid arthritis. Both assays were 
studied in a different way. The IBT was compared with more classical 
assays m different groups of sera, since it was only recently applied 
to serology of ANA. The APF was studied m different groups of pa-
tients, with special emphasis on its possible relation to disease seve-
nty. In addition, a possible etiologic agens for the APF was studied. 
Our findings will be summarized and discussed with reference to recent 
developments. 
Antinuclear antibody testing 
The use of IBT in ANA research has contributed a lot to the knowledge 
of nuclear antigens. ANA detected by routine IFT can now be defined 
more precisely. With one strip containing nuclear extract of HeLa cells 
(a human cervix carcinoma cell line) antibodies against nRNP, Sm, SS-B, 
centromere and Sc1-86 can be readily detected. Aside from these known 
specificities a number of different antibodies against nuclear antigens 
of unknown character exists (chapter 2, figure 3). Weakly stained bands 
show up with patients as well as healthy control sera. In sera of heal-
thy donors these patterns are donor specific and remain stable over ex-
tended periods of time. The IBT has proven very useful to characterize 
nuclear antigens that were known already from other assays. Anticentro-
mere antibodies are a good example. Firstly known to give a fine 
speckled pattern on HEp-2 cells, these antibodies later showed to react 
with an antigen in the centromere region as was seen on preparations of 
chromosome spreads. With IBT this antigen was identified as a 19kD an-
tigen m HeLa cells. The Sm and nRNP antigens were in this way charac-
terized to exist as complex antigens, composed of different proteins. 
So, starting from known specificities, biochemical data can be obtained 
by employing the IBT. Changes can be made in the separation of the pro-
teins to obtain information of the isoelectric point of the protein an-
tigens. Functional, biochemical and cytochemical capacities of these 
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proteins can be established. 
From the results obtained with IBT thus far, one can suspect that it is 
very difficult to identify new antigens, just by assaying groups of pa­
tients sera. The known and well characterized antigens (Sm, nRNP, SS-B 
and so on) give the strongest staining on blots. Many other bands are 
visible but staining is ]ust on the limits of detection. Here lies a 
major problem of the IBT described in this thesis: reproducibility of 
the test is of acceptable quality for the known antigens, but is of 
less quality in the lower range of staining. Even under the strictest 
test conditions vaguely visible bands can be absent when the same serum 
is assayed again. This is very discouraging and a major limitation of 
the IBT in a search for new antibody specificities and relations to 
(subsets of) rheumatic disease. It could be that these "minor" antigens 
are of "major" importance in antibody-disease relations. 
With these points in mind, the IBT is a useful addition in the scale of 
ANA assays. But the test has to be validated against other established 
assays. Since, for example anti-Sm antibody as detected by counterImmu­
noelectrophoresis (СІБ) is a criterium for the diagnosis SLE, on cannot 
change the antibody assay without being sure that he sensitivity and 
specificity are not affected. As is shown in chapter 3, IBT is more 
sensitive for anti-Sm antibody than the CIE. Anti Sm, detected by IBT 
can therefore not be accepted as a criterium of the set of ARA crite­
ria. In contrast to Sm, the IBT is less sensitive in the detection of 
anti-SS-B and anti-nPNP, all tested m the sera of SLE patients and 
compared with CIE. In addition, relations between results obtained with 
CIE and IBT, and clinical data are different. These matters are dis­
cussed extensively in chapter 3. 
A completely different way of comparing IBT with IFT and CIE is des­
cribed in chapter 4. In this chapter the IBT is used more or less as a 
"screening test" for ANA. Sera which were sent to a routine laboratory 
for ANA testing were tested in three assays and clinical information of 
the patients was obtained. Specificity and sensitivity of IBT and IFT 
were of comparable magnitude, for both assays (sens. 0.54 and 039, 
spec. 0.Θ2 and 0.79 for IFT and IBT respectively) while in contrast, 
the CIE combines a very high specificity (0.99) with an extremely low 
sensitivity (0.08). From this study it was concluded that ANA screening 
could be performed in the best way by means of an IFT, and that the IBT 
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Figure 1. "Future trends and developments" in research of generalized auto-immune diseases. 
could be used as a confirmation test. 
Since the introduction of the IBT, research has made great progress. 
Figure 1 depicts the lines along which, from different disciplines, 
further achievements can be awaited in the field of antinuclear antibo-
dies and their antigens. These lines of research will probably be of 
help in diagnosis of rheumatic diseases as well as in biochemistry re-
search (1,2,3,4). 
Antiperinuclear factor 
Antiperinuclear factor is known as an RA specific antibody, reactive 
with a cytoplasmic antigen present in keratohyaline bodies in human 
buccal mucosa cells. In the studies presented in chapter 5, a clear re-
lation is shown between the presence of APF and a more severe form of 
disease. A phenomenon, clearly seen in PF negative patients and to a 
lesser extent also seen in seropositive patients. This study combines 
two important points in the evaluation of patients sera in relation 
with disease severity. Firstly, when autoantibodies are studied, more 
serum samples taken with reasonable intervals, should be tested. 
Secondly, care should be taken to study variables that represent dis-
ease severity and not disease activity. 
Chapter 6 describes a relation between APF and with Epstein-Barr virus 
infection. This report adds a new phenomenon to the widely known rela-
tion between RA and EBV. Until now, no proof is given for a causative 
role of EBV in RA and the relations RA-APF and APF-EBV are not present-
ed as a conclusive argument in this debate. As is discussed in chapter 
6, the most likely possibility is an increased antigen-load (EBV) due 
to a decreased cytotoxic response against EBV. This antigen load leads 
to increased antibody responses. The EBV elicited antibody probably 
crossreacts with an auto-antigen present in human buccal mucosa cells. 
A point of criticism on the use of APF as a disgnostic test, is the 
lack of a reliable report on the predictive value of a positive test in 
patients with complaints and/or symptoms of arthritis. 
Chapter 7 describes the relations of ANA and APF with RF in patients 
with RA. Technical details of the respective assays are discussed, re-
ports on crossreactions and clinical data are evaluated and possible 
future research is discussed. 
From the ever increasing number of publications on cellular immunology, 
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one could get the impression that serologic research in auto-immune 
diseases is on the dead run. That is not true. As presented in this 
thesis, serologic assays could be included in the clinical management 
of patients with rheumatic diseases. And serologic research will un-
doubtedly continue to contribute to biological science and medical 
knowledge. 
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In dit proefschrift worden twee begrippen vaak gebruikt. Het eerste be-
grip is antistoffen. Kort gezegd zijn dat eiwitten die in ons bloed op-
gelost zijn en die een deel van het afweersysteem vormen. Wanneer we 
een infektie oplopen, produceren bepaalde cellen van ons immuunsysteem 
(afweersysteem, inmuunapparaat) deze antistoffen. Samen met behulp van 
de witte bloedlichaampjes kunnen de indringers (bacteri'én of virussen) 
opgeruimd worden. In deze funktie zijn antistoffen (immuunglobulinen) 
voor ons onmisbaar. Ze zijn in staat talloze (meer dan honderdduizendI) 
verschillende structuren te herkennen. Per liter bloed hebben we onge-
veer 15 gram afweerstoffen, plusminus een vijfde deel van de totale 
hoeveelheid eiwit in het bloed. 
Er zijn een aantal ziekten bekend waarbij deze antistoffen een wat an-
der "karakter" blijken te hebben. Ze reageren met structuren in ons 
eigen lichaam en heten daarom auto-antistoffen (auto « zelf). Normaal 
kan ons lichaam dat onderdrukken, maar bij deze zogenaamde auto-immuun-
ziekten is het afweerapparaat verstoord (de redenen daarvoor zijn niet 
bekend). 
Auto-immuunziekten is het tweede begrip dat centraal staat in dit 
proefschrift. Omdat veel van de klachten gewrichten of spieren betref-
fen, worden veel van deze ziekten door een reumatoloog behandeld. Het 
zijn ziekten die zich vaak niet tot gewrichten of spieren beperken, 
maar ook organen zoals nieren, huid of hart kunnen aantasten. Om een 
aantal van de bekendste te noemen: reumatoide arthritis, systemische 
lupus erythematosus, sclerodermie, myositis; een zeer onvolledige 
lijst, maar dit zijn de bekendste. Het stellen van dit soort diagnoses 
is, ook voor een ervaren reumatoloog, niet altijd gemakkelijk. Zoals zo 
vaak in de geneeskunde, wordt gebruik gemaakt van laboratorium tests. 
En daar komen dan die auto-antistof f en weer om de hoek kijken. Het is 
in het verleden gebleken dat die auto-antistoffen op te splitsen zijn 
in een aantal groepen. ledere groep is weer onder te verdelen in een 
aantal zogenaamde specificitelten. Een van die groepen is de groep an-
tikern antistoffen (antinucléaire antistoffen). Enkele specificitelten 
van deze groep zijn bijvoorbeeld anti-DNA, anti-Sm, anti-nRNP of anti-
centromeer. Voor al dit soort antistoffen zijn in het verleden heel 
bijzondere tests ontwikkeld. Als in het bloed van een patient dit soort 
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antistoffen aanwezig zijn, dan is dat een aanwijzing voor een bepaalde 
diagnose. De diagnose van auto-immuunzlekten berust dus in belangrijke 
mate op klachten van de patient en wordt ondersteund door bepaling van 
specifieke antistoffen. 
In het begin van de jaren tachtig is een nieuwe test uitgevonden: de 
immunoblottest. Het is een fraaie (zie figuren in hoofdstukken 2 en 3) 
maar bewerkelijke techniek. In hoofdstuk 2 wordt een nieuw apparaat be-
schreven dat de bewerkingen in de blottest een stuk eenvoudiger maakt. 
In dit proefschrift wordt in de hoofdstukken 3 en 4 onderzoek beschre-
ven waarin deze blottest vergeleken wordt met de oudere reeds bekende 
tests. De blottest moest eerst "geijkt" worden, zoals een weegschaal, 
meetlat of thermometer geijkt moet worden voordat betrouwbaar gemeten 
of gewogen kan worden. De uitslag was niet ongunstig voor de blottest. 
De test is redelijk betrouwbaar en vergelijkbaar met de bekende tests. 
Omdat het een nogal bewerkelijke test is, zullen we er in de toekomst 
spaarzaam gebruik van moeten maken. Wel is het zo dat het fundamenteel 
wetenschappelijk onderzoek ("Hoe zit dit in elkaar", "Wat is...", 
"Waarom...") met behulp van deze techniek reeds stappen vooruit maakte 
en er ook in de toekomst waarschijnlijk veel profijt van zal hebben. 
Het tweede deel van dit proefschrift (hoofdstukken 5,6 en 7) beschrijft 
onderzoek van een andere test en een bijzondere antistof. Deze anti-
stof, die we antiperinucleaire factor (APP) noemen, komt bijna alleen 
voor bij patiënten met reumatoide artritis. De test noemen we APF test. 
Waarom patiënten deze antistoffen hebben is niet bekend, maar in hoofd-
stuk 6 wordt beschreven dat deze antistof kan ontstaan na een infectie 
met Epstein-Barr virus (het virus dat de ziekte van Pfeiffer (= klier-
koorts) veroorzaakt). Nu is al lang bekend dat patiënten met reumatoide 
arthritis meer antistoffen tegen dit virus hebben, waarschijnlijk omdat 
hun afweer tegen het virus minder is dan bij gezonden. De oorzaak van 
de APF zou dus bij het Epstein-Barr virus kunnen liggen. 
In hoofdstuk 6 wordt beschreven hoe de relatie tussen APF en de ernst 
van de ziekte is. Het blijkt dat patiënten met deze antistof, gemiddeld 
genomen, een grotere kans hebben om aantasting van de gewrichten te 
krijgen. Van een andere antistof, de reumafaktor, was dat al lang be-
kend. Wel moet worden bedacht dat op deze regel talloze uitzonderingen 
bestaan. 
In hoofdstuk 7 worden de zaken nog ingewikkelder; de relaties tussen de 
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verschillende antistoffen worden besproken. Het lijkt er op dat êén 
sleutel (antistof) op meerdere sloten past of dat één slot door meerde-
re sleutels (antistoffen) geopend kan worden. Antistoffen kunnen elkaar 
"imiteren". We noemen dat kruisreakties. Dit zijn zaken die voor diag-
nose en behandeling van minder belang zijn, maar die de voortgang van 
het wetenschappelijk onderzoek wel in een bepaalde richting kunnen stu-
ren. 
Een blik in de toekomst wordt in hoofdstuk θ beschreven, samen met een 
samenvatting van het onderzoek. 
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The Road goes ever on and on 
Out from the door where it began. 
Now far ahead the Road has gone, 
Let others follow it who cani 
Let them a journey new begin, 
But I at last with weary feet 
Will turn towards the lighted inn, 
My evening-rest and sleep to meet. 
The Lord of the Rings, 
JRR Tolkien 
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STELLINGEN 
1 Anti-Sm antistoffen, gedetecteerd met de immunoblottest zijn geen 
criterium voor Systemische Lupus Erythematosus. 
Dit proefschrift 
2 De immunoblottest en kopieermachines zijn onverenigbare 
verworvenheden van de moderne techniek. 
Kopieën van dit proefschrift 
3 Bepaling van de Antiperinucleaire Factor heeft niet zozeer diagnostische 
alswel prognostische waarde. 
Dit proefschrift 
4 Omdat de Antiperinucleaire Factor zijn status als antistof voldoende 
bewezen heeft en omdat nefrologen, net zoals ze met de term AN F deden, 
binnenkort de term APF wel zullen claimen, moet voortaan de afkorting 
APA gebruikt worden. 
5 De begrippen Specificiteit en Sensitiviteit zijn belangrijke begrippen m.b.t. 
een test voor 'Ziek of Gezond'. Deze parameters worden meestal in de 
verkeerde groepen patiënten en controles bestudeerd en geven bovendien 
niet de belangrijkste karakteristiek van de test weer: de voorspellende 
waarde van een positieve of negatieve uitslag. 
Dit proefschrift 
6 Sommige processen van het immuunsysteem vertonen veel overeenkomst 
met het gedrag van het Israëlische leger in de bezette gebieden. 
I.R. Cohen, The self, the world and auto-immunity. 
Scientific American: 258, 4, 34-42, 1988. 
7 De Nederlandse Spoorwegen discrimineren niet-rokcrs door coupé's voor 
deze reizigers stelselmatig boven de wielstellen te plaatsen. 
8 Het moet verboden worden dat vrouwen bij het huwelijk de achternaam 
van hun man aannemen. 
9 Bepalingen voor Reumafactoren moeten uitgevoerd worden in een 
laboratorium met kennis van en wetenschappelijke interesse in auto­
antistoffen. 
10 Omdat hij geen pony's mishandelt of een gcboortekrik gebruikt; omdat 
hij niet te hard rijdt of onder invloed aan het verkeer deelneemt en 
omdat hij niet met voorkennis in aandelen handelt blijft de vraag wat de 
Minister van Onderwijs en Wetenschappen dan moet doen om ongeschikt 
verklaard te worden voor zijn taak. 
11 АСА (Anticentromeer antistoffen) en АСА (Anticardiolipine antistoffen) 
zijn geen ANAloge termen. 
12 Telefoneren is soms de snelste manier van T-cel doneren. 
13 Artsen verdienen niet zoveel. 
14 Gevoelens van opluchting van een promovendus en dankbaarheid jegens 
collega's en medewerkers zijn niet alleen tot uitdrukking te brengen door 
het geven van een kostbaar feest. 
Stellingen behorend bij het proefschrift 'Autoantibodies in Rheumatic 
Diseases' van Toon Westgeest. 
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